<SEC-DOCUMENT>0001193125-21-346821.txt : 20211202
<SEC-HEADER>0001193125-21-346821.hdr.sgml : 20211202
<ACCEPTANCE-DATETIME>20211202171538
ACCESSION NUMBER:		0001193125-21-346821
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		4
FILED AS OF DATE:		20211202
DATE AS OF CHANGE:		20211202

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MEI Pharma, Inc.
		CENTRAL INDEX KEY:			0001262104
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				510407811
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-238056
		FILM NUMBER:		211467756

	BUSINESS ADDRESS:	
		STREET 1:		11455 EL CAMINO REAL
		STREET 2:		SUITE 250
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		858-369-7100

	MAIL ADDRESS:	
		STREET 1:		11455 EL CAMINO REAL
		STREET 2:		SUITE 250
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MARSHALL EDWARDS INC
		DATE OF NAME CHANGE:	20030902
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>d236540d424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML><HEAD>
<TITLE>424B5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(5)<BR>Registration Statement No. 333-238056 </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>PROSPECTUS SUPPLEMENT </B><BR>(TO PROSPECTUS DATED MAY&nbsp;18, 2020) </P>
<P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>17,500,000 Shares </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g236540g63p02.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>Common Stock </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We are
offering 17,500,000 shares of common stock, par value $0.00000002 per share. Our common stock is listed on the Nasdaq Capital Market under the symbol &#147;MEIP.&#148; The last reported sale price of our common stock on the Nasdaq Capital Market on
December&nbsp;1, 2021 was $3.03 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>An investment in our common stock involves significant risks. You should carefully consider the Risk Factors
beginning on page&nbsp;<A HREF="#supprom236540_4"><FONT STYLE="white-space:nowrap">S-14</FONT></A> of this prospectus supplement and page&nbsp;
<A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1262104/000095017021001655/meip-20210630.htm#d58841d10k_htm_toc58841_3">22</A> of our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed with
the Securities and Exchange Commission on September&nbsp;2, 2021, before investing in our common stock. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Neither the Securities and Exchange Commission nor
any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement and the accompanying base prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PER&nbsp;SHARE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">45,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Underwriting discounts<SUP STYLE="font-size:85%; vertical-align:top"> (1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,730,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Proceeds, before expenses, to us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.444</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">42,770,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">See the section entitled &#147;Underwriting&#148; for additional information regarding underwriter compensation. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We
have granted the underwriters an option exercisable for up to 30 days from the date of this prospectus supplement to purchase up to 2,625,000 additional shares of common stock at the public offering price less underwriting discounts. If this option
were exercised in full, we would receive approximately $6,415,500 of additional proceeds, before expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The underwriters expect to deliver the shares of common
stock to the purchasers on or about December 6, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>Joint Book-Running Managers </I></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:16pt" ALIGN="center">


<TR>

<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:16pt">
<TD VALIGN="top" COLSPAN="3"><B>Jefferies</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Stifel</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3" ALIGN="right"><B>Wells&nbsp;Fargo&nbsp;Securities</B></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>Co-Managers </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:14pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:14pt">
<TD VALIGN="top" ALIGN="center"><B>LifeSci Capital</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>H.C. Wainwright &amp; Co.</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">The date of this prospectus supplement is December&nbsp;1, 2021. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Prospectus Supplement </B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#supprom236540_1">ABOUT THIS PROSPECTUS SUPPLEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-iii</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#supprom236540_2">CAUTIONARY STATEMENT ABOUT FORWARD-LOOKING STATEMENTS </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-iv</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#supprom236540_3">SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#supprom236540_4">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#supprom236540_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#supprom236540_6">DILUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-18</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#supprom236540_7">UNDERWRITING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#supprom236540_8">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#supprom236540_9">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#supprom236540_10">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#supprom236540_11">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Prospectus </B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="98%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc236540_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc236540_2">SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc236540_3">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc236540_4">CAUTIONARY STATEMENT ABOUT FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc236540_5">SECURITIES OFFERED BY THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc236540_6">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc236540_7">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc236540_8">DESCRIPTION OF SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc236540_9">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc236540_10">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc236540_11">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc236540_12">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">You should rely only on the information contained in or incorporated by reference into this prospectus supplement and
the accompanying base prospectus and any free writing prospectuses prepared by us or on our behalf. We have not authorized any person to provide any information or make any statement that differs from what is contained in this prospectus supplement,
the accompanying base prospectus and any free writing prospectuses prepared by us or on our behalf. If any person does make a statement that differs from what is in this prospectus supplement, the accompanying base prospectus or any free writing
prospectuses, you should not rely on it. This prospectus supplement is not an offer to sell, nor is it a solicitation of an offer to buy, these securities in any jurisdiction in which the offer or sale is not permitted. You should assume that the
information contained in this prospectus supplement, the accompanying base prospectus, any free writing prospectus and the documents incorporated by reference is accurate only as of its respective date, regardless of the time of delivery of this
prospectus supplement, the accompanying base prospectus, any free writing prospectus or of any sale of shares of our common stock in this offering. Our business, financial condition, results of operations and prospects may have subsequently changed.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="supprom236540_1"></A>ABOUT THIS PROSPECTUS SUPPLEMENT </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus supplement and the accompanying base prospectus are part of a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> that we filed
with the Securities and Exchange Commission, or SEC, using a &#147;shelf&#148; registration statement. Under the shelf registration statement, we may offer and sell any combination of securities described in the accompanying base prospectus in one
or more offerings. The accompanying base prospectus provides you with a general description of the securities we may offer. Each time we use the accompanying base prospectus to offer securities, we will provide a prospectus supplement that will
contain specific information about the terms of that offering. The prospectus supplement may also add, update or change information contained in the accompanying base prospectus. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus supplement, the accompanying base prospectus and the documents incorporated by reference herein include important information about us, our common stock
and other information you should know before investing. This prospectus supplement describes the specific details regarding this offering, including the price, the amount of common stock being offered and the risks of investing in our common stock.
The accompanying base prospectus provides general information about us, some of which may not apply to this offering. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To the extent that any statement that we make
in this prospectus supplement is inconsistent with statements made in the accompanying base prospectus, the statements made in this prospectus supplement will be deemed to modify or supersede those made in the accompanying base prospectus. You
should read both this prospectus supplement and the accompanying base prospectus together with additional information described under the heading, &#147;Where You Can Find More Information.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-iii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B><A NAME="supprom236540_2"></A>CAUTIONARY STATEMENT ABOUT FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">This prospectus supplement and the documents incorporated by reference herein include forward-looking statements within the meaning of Section&nbsp;27A of the
Securities Act of 1933, as amended (the &#147;Securities Act&#148;) and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;). All statements other than statements of historical facts contained in this
prospectus supplement and in the documents incorporated by reference herein, including statements regarding the future financial position, business strategy and plans and objectives of management for future operations, are forward-looking
statements. The words &#147;believe,&#148; &#147;may,&#148; &#147;will,&#148; &#147;estimate,&#148; &#147;continue,&#148; &#147;anticipate,&#148; &#147;intend,&#148; &#147;should,&#148; &#147;plan,&#148; &#147;expect,&#148; and similar expressions,
as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on current expectations and projections about future events and financial trends that we believe may affect our
financial condition, results of operations, business strategy and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, without limitation, those described in &#147;Risk
Factors&#148; in this prospectus supplement and in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended June&nbsp;30, 2021, including, among other things: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8.5pt">We will need substantial additional funds to progress the clinical trial programs for our drug candidates, to
commercialize our drug candidates, and to develop new compounds. The actual amount of funds we will need will be determined by a number of factors, some of which are beyond our control; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8.5pt">We are a late stage clinical research and development stage company and are likely to incur operating losses for the
foreseeable future; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8.5pt">The results of <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and completed clinical trials are not
necessarily predictive of future results, and our current drug candidates may not have favorable results in later studies or trials; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8.5pt">Final data from our <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and completed clinical trials may differ
materially from reported interim data from ongoing studies and trials; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8.5pt">The outbreak of the novel coronavirus disease, <FONT STYLE="white-space:nowrap">COVID-19,</FONT> or other pandemic,
epidemic or outbreak of an infectious disease may materially and adversely impact our business, including our <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8.5pt">Changes in drug candidate manufacturing or formulation may result in additional costs or delay; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8.5pt">If KKC or other parties with whom we collaborate on the development and commercialization of our drug candidates do not
satisfy their obligations, do not otherwise pursue development or commercialization of our drug candidates or if they terminate their agreements with us, we may not be able to develop or commercialize our drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8.5pt">We are subject to significant obligations to Presage in connection with our license of voruciclib, and we may become
subject to significant obligations in connection with future licenses we obtain, which could adversely affect the overall profitability of any products we may seek to commercialize, and such licenses of drug candidates, the development and
commercialization for which we are solely responsible, may never become profitable; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8.5pt">Our business strategy may include entry into additional collaborative or license agreements. We may not be able to enter
into collaborative or license agreements or may not be able to negotiate commercially acceptable terms for these agreements; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8.5pt">Final approval by regulatory authorities of our drug candidates for commercial use may be delayed, limited or prevented,
any of which would adversely affect our ability to generate operating revenues; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8.5pt">The FDA may determine that our drug candidates have undesirable side effects that could delay or prevent their regulatory
approval or commercialization; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8.5pt">If we experience delays or difficulties in the enrolment of patients in clinical trials, our completion of clinical trials
and receipt of necessary regulatory approvals could be delayed or prevented; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8.5pt">Changes in funding for the FDA and other government agencies or future government shutdowns could cause delays in the
submission and regulatory review of marketing applications, which could negatively impact our business or prospects; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8.5pt">Failure to obtain regulatory approval in foreign jurisdictions would prevent us from marketing our products
internationally; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8.5pt">Any designation granted by the FDA for any of our product candidates may not lead to a faster development or regulatory
review or approval process, and does not increase the likelihood that our product candidates will receive marketing approval. We may also not be able to obtain or maintain any such designation; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8.5pt">Any orphan drug designations we receive may not confer marketing exclusivity or other benefits; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8.5pt">Even if we or our licensees receive regulatory approval to commercialize our drug candidates, our ability to generate
revenues from any resulting products will be subject to a variety of risks, many of which are out of our control; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8.5pt">If any products we develop become subject to unfavorable pricing regulations, third-party reimbursement practices or
healthcare reform initiatives, our ability to successfully commercialize our products will be impaired; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8.5pt">Our drug candidates are subject to ongoing government regulation both before and after regulatory approval;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8.5pt">We may not be able to establish the contractual arrangements necessary to develop, market and distribute our drug
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8.5pt">Our commercial opportunity will be reduced or eliminated if competitors develop and market products that are more
effective, have fewer side effects or are less expensive than our drug candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8.5pt">Our product candidates may face competition sooner than anticipated; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8.5pt">We rely on third parties to conduct our clinical trials and <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies.
If those parties do not successfully carry out their contractual duties or meet expected deadlines, our drug candidates may not advance in a timely manner or at all; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-iv </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8.5pt">We will depend on third party suppliers and contract manufacturers for the manufacturing of our drug candidates and have
no direct control over the cost of manufacturing our drug candidates. Increases in the cost of manufacturing our drug candidates would increase our costs of conducting clinical trials and could adversely affect our future profitability;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8.5pt">We rely on acquisitions or licenses from third parties to expand our pipeline of drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8.5pt">Our commercial success is dependent, in part, on obtaining and maintaining patent protection and preserving trade secrets,
which cannot be guaranteed; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8.5pt">Claims by other companies that we infringe on their proprietary technology may result in liability for damages or stop our
development and commercialization efforts; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8.5pt">We may be subject to claims by third parties asserting that our employees or we have misappropriated their intellectual
property, or claiming ownership of what we regard as our own intellectual property; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8.5pt">We may be subject to substantial costs stemming from our defense against third-party intellectual property infringement
claims; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8.5pt">We face a risk of product liability claims and claims may exceed our insurance limits; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8.5pt">Our employees, independent contractors, consultants, commercial partners, principal investigators, or CROs may engage in
misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse effect on our business; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8.5pt">Our business and operations would suffer in the event of system failures; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8.5pt">Our efforts will be seriously jeopardized if we are unable to retain and attract key employees; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8.5pt">Negative U.S. and global economic conditions may pose challenges to our business strategy, which relies on funding from
the financial markets or collaborators; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8.5pt">Laws, rules and regulations relating to public companies may be costly and impact our ability to attract and retain
directors and executive officers; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8.5pt">If we fail to establish and maintain proper and effective internal controls, our ability to produce accurate financial
statements on a timely basis could be impaired, which would adversely affect our operating results, our ability to operate our business, and our stock price, and could result in litigation or similar actions; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8.5pt">Security breaches and other disruptions could compromise our information and expose us to liability, which would cause our
business and reputation to suffer; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8.5pt">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or
penalties or incur costs that could harm our business; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8.5pt">We or the third parties upon whom we depend may be adversely affected by natural disasters and our business continuity and
disaster recovery plans may not adequately protect us from a serious disaster; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8.5pt">Limitations on the deductibility of net operating losses could adversely affect our business and financial condition;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8.5pt">The trading price of the shares of our common stock has been and may continue to be highly volatile and could decline in
value and we may incur significant costs from class action litigation; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8.5pt">Future sales of our common stock, including common stock issued upon exercise of outstanding warrants or options, may
depress the market price of our common stock and cause stockholders to experience dilution; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8.5pt">Because we do not intend to pay, and have not paid, any cash dividends on our shares of common stock, our stockholders
will not be able to receive a return on their shares unless the value of our common stock appreciates and they sell their shares; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8.5pt">We will have broad discretion over the use of the net proceeds from any exercise of outstanding warrants and options;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8.5pt">We are authorized to issue blank check preferred stock, which could adversely affect the holders of our common stock;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8.5pt">Anti-takeover provisions contained in our amended and restated certificate of incorporation and third amended and restated
bylaws, as well as provisions of Delaware law, could impair a takeover attempt; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8.5pt">Our third amended and restated bylaws require, to the fullest extent permitted by law, that derivative actions brought in
our name, actions against our directors, officers, other employees or stockholders for breach of fiduciary duty and other similar actions may be brought only in the Court of Chancery in the State of Delaware and, if brought outside of Delaware, the
stockholder bringing the suit will be deemed to have consented to service of process on such stockholder&#146;s counsel, which may have the effect of discouraging lawsuits against our directors, officers, other employees or stockholders; and
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8.5pt">Our executive officers and directors may sell shares of their stock, and these sales could adversely affect our stock
price. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">These risks are not exhaustive. Other sections of this prospectus supplement and the documents incorporated by reference herein include
additional factors which could adversely impact our business and financial performance. Moreover, we operate in a very competitive and rapidly changing environment. New risk factors emerge from time to time and it is not possible for us to predict
all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">You should not rely upon forward looking statements as predictions of future events. We cannot assure you that the events and circumstances reflected in the forward
looking statements will be achieved or occur. Although we believe that the expectations reflected in the forward looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-v </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="supprom236540_3"></A>SUMMARY </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>This summary highlights selected information appearing elsewhere or incorporated by reference in this prospectus supplement and accompanying base prospectus and may
not contain all of the information that is important to you. This prospectus supplement and the accompanying base prospectus include or incorporate by reference information about the shares we are offering as well as information regarding our
business, risks and detailed financial data. You should read this prospectus supplement and the accompanying base prospectus in their entirety, including the information incorporated by reference. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>The Company </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are a late-stage pharmaceutical company committed to the
development and commercialization of novel cancer therapies intended to improve outcomes for patients. Our portfolio of drug candidates has three clinical-stage assets, including zandelisib, currently in multiple ongoing clinical studies intended to
support marketing applications with the U.S. Food and Drug Administration (&#147;FDA&#148;) and other regulatory authorities globally. Our common stock is listed on the NASDAQ Capital Market under the symbol &#147;MEIP.&#148; </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our approach to building our pipeline is to license or acquire promising cancer agents and build value in programs through development, commercialization and strategic
partnerships, as appropriate. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As a result of the ongoing and rapidly evolving <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, various public health
orders and guidance measures have been implemented across much of the United States, and across the globe, including in the locations of our office, clinical trial sites, key vendors and partners. The <FONT STYLE="white-space:nowrap">COVID-19</FONT>
virus may continue to mutate into different strains, which could be more contagious or severe or for which current vaccines and treatments are not effective or available. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">While we continue to enroll and dose patients in our clinical trials, certain of our clinical trials evaluating zandelisib and voruciclib have been delayed due to <FONT
STYLE="white-space:nowrap">COVID-19,</FONT> and our clinical development program timelines may continue to be subject to potential negative impacts from the ongoing pandemic in the U.S. and globally. The extent to which the ongoing pandemic
continues to impact our business, including our <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies, chemistry, manufacturing and controls (&#147;CMC&#148;) studies, manufacturing, and clinical trials, will depend on future developments,
which are highly uncertain and cannot be predicted with confidence including the ultimate geographic spread of the disease, the duration of the pandemic, the development, effectiveness and timing of distribution of treatments and vaccines for <FONT
STYLE="white-space:nowrap">COVID-19,</FONT> travel restrictions and social distancing in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries
to contain and treat the disease and to minimize its economic impact, including vaccination rates and effectiveness. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Clinical Development Programs </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We build our pipeline by licensing or acquiring promising cancer agents and creating value in programs through development, commercialization and strategic
partnerships, as appropriate. Our objective is to leverage the mechanisms and properties of our pipeline drug candidates to optimize the balance between efficacy and tolerability to meet the needs of patients with cancer. Our drug candidate pipeline
includes: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Zandelisib (f/k/a <FONT STYLE="white-space:nowrap">ME-401),</FONT> an oral phosphatidylinositol <FONT
STYLE="white-space:nowrap">3-kinase</FONT> (&#147;PI3K&#148;) delta inhibitor; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Voruciclib, an oral cyclin-dependent kinase 9 (&#147;CDK9&#148;) inhibitor; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><FONT STYLE="white-space:nowrap">ME-344,</FONT> a mitochondrial inhibitor targeting the oxidative phosphorylation
(&#147;OXPHOS&#148;) complex. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g236540g09h85.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">1.</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Phase 2 study intended to support accelerated approval marketing applications with the FDA, subject to results and discussions with FDA. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">2.</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Study arm initiated under clinical collaboration with BeiGene, Ltd. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">3.</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Investigator-initiated trial. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">4.</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Initiation of clinical studies is subject to opening of a new Investigational New Drug Application (&#147;IND&#148;) with the FDA. </TD></TR></TABLE>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Zandelisib:
PI3K</I></B><FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT></FONT><FONT STYLE="font-family:ARIAL"><B><I></I></B></FONT><B><I> Inhibitor in Multiple Trials Intended to Support Marketing Approvals in Relapsed
or Refractory Follicular and Marginal Zone Lymphomas </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Zandelisib is an oral, once-daily, selective PI3K<FONT STYLE="font-family:Times New Roman"><FONT
STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT></FONT> inhibitor in clinical development for the treatment of <FONT STYLE="white-space:nowrap">B-cell</FONT> malignancies. In March 2020, the FDA granted zandelisib Fast Track designation for the treatment of
adult patients with relapsed or refractory (&#147;r/r&#148;) follicular lymphoma (&#147;FL&#148;) who have received at least two prior systemic therapies. In November 2021, the FDA granted zandelisib Orphan Drug designation for the treatment of
patients with follicular lymphoma. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In April 2020, we entered into a global license, development and commercialization agreement to further develop and
commercialize zandelisib with Kyowa Kirin Co., Ltd. (&#147;KKC&#148;). MEI and KKC will <FONT STYLE="white-space:nowrap">co-develop</FONT> and <FONT STYLE="white-space:nowrap">co-promote</FONT> zandelisib in the U.S., with MEI recording all revenue
from U.S. sales. KKC has exclusive commercialization rights outside of the U.S. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are conducting multiple ongoing studies evaluating zandelisib. Our studies
include TIDAL, a Phase 2 study evaluating zandelisib as a monotherapy in patients with r/r FL and marginal zone lymphoma (&#147;MZL&#148;) patients who have received at least two prior systemic therapies which must have included chemotherapy with an
alkylating agent and an anti-CD20 antibody. Enrollment of the MZL arm remains ongoing. Subject to the results and discussions with FDSA, data from TIDAL is intended to support submissions for accelerated approval marketing applications with the FDA
in r/r FL and MZL patients receiving at least two prior lines of systemic treatment. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On November&nbsp;30, 2021, we announced that our pivotal Phase 2 TIDAL
study<B> </B>evaluating zandelisib as a single agent for the treatment of FL patients who received at least two prior of lines of systemic therapy demonstrated a 70.3% objective response rate (ORR) as determined by Independent Review Committee (IRC)
assessment in the primary efficacy population (n=91). In addition, 35.2% of patients achieved a complete response. The data are currently insufficiently mature to accurately estimate duration of response (DOR). In line with previously reported data
from the Phase 1B study, zandelisib was generally well tolerated. With 9.4 months&nbsp;(range: <FONT STYLE="white-space:nowrap">0.8-24)</FONT> median duration of <FONT STYLE="white-space:nowrap">follow-up</FONT> in the total study population
(n=121),&nbsp;interim data demonstrated a discontinuation rate due to any drug related adverse event of 9.9%. Patients enrolled in the study will continue to be followed for safety and DOR. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">COASTAL, the Phase 3 study evaluating zandelisib in combination with rituximab in patients with r/r FL and MZL who
have received at least one prior line of treatment, is intended to support full marketing applications in the U.S. and globally in r/r FL and MZL patients receiving at least one prior line of systemic treatment. COASTAL is also intended (subject to
FDA agreement) to potentially act as a confirmatory study if zandelisib receives U.S. accelerated approvals based on the TIDAL study. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are also conducting a <FONT
STYLE="white-space:nowrap">multi-arm,</FONT> open-label, Phase 1b dose finding and expansion trial evaluating zandelisib as a monotherapy and in combination with other therapies in patients with relapsed or refractory
<FONT STYLE="white-space:nowrap">B-cell</FONT> malignancies. Other initiated studies include Phase 1 and Phase 2 studies being conducted by KKC evaluating zandelisib as a monotherapy in patients in Japan with indolent
<FONT STYLE="white-space:nowrap">B-cell</FONT> malignancy pursuant to our agreement with KKC. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Zandelisib: Potentially Highly Differentiated Pharmaceutical
Properties within a Clinically Validated Class&nbsp;of Treatments </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">While
PI3K<FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT></FONT> inhibitors as a group are a clinically validated class for the treatment of <FONT STYLE="white-space:nowrap">B-cell</FONT> malignancies, the FDA
approved orally administered products, idelalisib (marketed as Zydelig<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>), duvelisib (marketed as COPIKTRA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>), umbralisib (marketed as
UKONIQ<SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP>), and the intravenously administered PI3K<FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT></FONT>/<FONT STYLE="font-family:Times New Roman"><FONT
STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT></FONT> inhibitor copanlisib (marketed as Aliqopa<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>), are challenged by dose-limiting toxicities, modest efficacy and/or inconvenience of administration
route. We believe this provides an opportunity for the development of a next-generation candidate with pharmaceutical properties that may better maximize the therapeutic potential of PI3K<FONT STYLE="font-family:Times New Roman"><FONT
STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT></FONT> inhibition by limiting toxicities and improving upon modest efficacy, which together hinder clinical utility. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
molecular structure and pharmacodynamic characteristics of zandelisib are distinct from the FDA approved PI3K<FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT></FONT> inhibitors. Zandelisib&#146;s distinct
characteristics include prolonged target binding, preferential cellular accumulation, high volume of distribution throughout the body tissues, and an approximately <FONT STYLE="white-space:nowrap">28-hour</FONT> half-life suitable for once daily
oral administration. The properties of zandelisib support exploration of flexible dosing regimens such as an intermittent dosing schedule, which has clinically demonstrated to date the potential to maintain clinical benefit while minimizing
immune-related toxicities common to other PI3K<FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT></FONT> agents, either as a monotherapy or in combination with other therapies. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>KKC License, Development and Commercialization Agreement </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In April 2020, we
entered into a License, Development and Commercialization Agreement with KKC (the &#147;KKC Commercialization Agreement&#148;). We granted to KKC a <FONT STYLE="white-space:nowrap">co-exclusive,</FONT> sublicensable, payment-bearing license under
certain patents and <FONT STYLE="white-space:nowrap">know-how</FONT> controlled by us to develop and commercialize zandelisib and any pharmaceutical product containing zandelisib for all human indications in the U.S., and an exclusive (subject to
certain retained rights to perform obligations under the agreement), sublicensable, payment-bearing, license under certain patents and <FONT STYLE="white-space:nowrap">know-how</FONT> controlled by us to develop and commercialize zandelisib and any
pharmaceutical product containing zandelisib for all human indications in countries outside of the United States (the <FONT STYLE="white-space:nowrap">&#147;Ex-U.S&#148;).</FONT> KKC grants to us a
<FONT STYLE="white-space:nowrap">co-exclusive,</FONT> sublicensable, license under certain patents and <FONT STYLE="white-space:nowrap">know-how</FONT> controlled by KKC to develop and commercialize zandelisib for all human indications in the U.S.,
and a <FONT STYLE="white-space:nowrap">co-exclusive,</FONT> sublicensable, royalty-free, fully paid license under certain patents and <FONT STYLE="white-space:nowrap">know-how</FONT> controlled by KKC to perform our obligations in the <FONT
STYLE="white-space:nowrap">Ex-U.S.</FONT> under the KKC Commercialization Agreement. The KKC Commercialization Agreement substantially retains and consolidates the terms of the 2018 license agreement with KKC to develop and commercialize zandelisib
in Japan. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">KKC will be responsible for the development and commercialization of zandelisib in the <FONT STYLE="white-space:nowrap">Ex-U.S.</FONT> and, subject to
certain exceptions, will be solely responsible for all costs related thereto. We will <FONT STYLE="white-space:nowrap">co-develop</FONT> and <FONT STYLE="white-space:nowrap">co-promote</FONT> zandelisib with KKC in the U.S., with the Company
recording all revenue from U.S. sales. We will share U.S. profits and costs (including development costs) on a <FONT STYLE="white-space:nowrap">50-50</FONT> basis with KKC. We will also provide to KKC certain drug supplies necessary for the
development and commercialization of zandelisib in the <FONT STYLE="white-space:nowrap">Ex-U.S.</FONT> pursuant to supply agreements to be entered into on customary terms, with the understanding that KKC will assume responsibility for manufacturing
for the <FONT STYLE="white-space:nowrap">Ex-U.S.</FONT> as soon as practicable. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the terms of the KKC Commercialization Agreement, KKC paid us an initial payment of $100&nbsp;million. We may
also earn up to approximately $582.5&nbsp;million in potential development, regulatory and commercialization milestone payments, plus royalties on net sales of zandelisib in the <FONT STYLE="white-space:nowrap">Ex-U.S.,</FONT> which are tiered
beginning in the teens. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Zandelisib Scientific Overview: at the Crossroads of <FONT STYLE="white-space:nowrap">B-cell</FONT> Signaling Pathways </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The PI3K/AKT/mTOR pathway is an important signaling pathway for many cellular functions such as cell survival, cell cycle progression and cellular growth. PI3Ks are a
family of enzymes within this pathway that have been shown to play a critical role in the proliferation and survival of certain cancer cells. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There are several
isoforms of PI3K that are expressed in different types of cells. The PI3K<FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT></FONT> isoform is at the crossroads of <FONT STYLE="white-space:nowrap">B-cell</FONT>
receptor signaling pathways that are major drivers of survival and proliferation of many <FONT STYLE="white-space:nowrap">B-cell</FONT> malignancies. Because the
<FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT></FONT> isoform is often overexpressed in cancer cells of the <FONT STYLE="white-space:nowrap">B-lymphocyte</FONT> lineage, such as <FONT
STYLE="white-space:nowrap">B-cell</FONT> leukemias and lymphomas, it is understood to be important for survival of these cells. Zandelisib displays high selectivity for the PI3K delta isoform and functions to inhibit its activity.</P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Clinical Program Overview </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are conducting multiple ongoing studies
evaluating zandelisib including TIDAL, a global Phase 2 trial evaluating patients with r/r FL and MZL with at least two prior of lines of therapy that, subject to the results and discussions with FDA, is intended to support FDA marketing
applications for accelerated approval. The objective response rate in the FL cohort of TIDAL, the study&#146;s primary outcome measure, is 70.3%. In addition, 35.2% of patients achieved a complete response. Evaluation of the FL cohort remains
ongoing for duration of response and safety. The study is also continuing to enroll patients for the MZL cohort. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Subject to final results and discussions with the
FDA, the TIDAL study is intended to support submissions for accelerated approval marketing applications with the FDA in r/r FL and MZL patients receiving at least two prior lines of systemic treatment. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Also ongoing is COASTAL, a global Phase 3 study evaluating patients with r/r FL and MZL with at least one prior line of therapy. COASTAL is intended to support full
marketing applications in the U.S. and globally in r/r FL and MZL patients receiving at least one prior line of systemic treatment. COASTAL is also intended (subject to FDA agreement) to potentially act as a confirmatory study if zandelisib receives
U.S. accelerated approvals based on the TIDAL study. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Additionally, we are conducting a <FONT STYLE="white-space:nowrap">multi-arm,</FONT> open-label, Phase 1b dose
escalation and expansion trial as a monotherapy and in combination with other therapies, therapies in patients with FL and other <FONT STYLE="white-space:nowrap">B-cell</FONT> malignancies. The Phase 1b trial includes an arm exploring zandelisib in
combination with rituximab (Rituxan<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>) and an arm exploring zandelisib in combination with zanubrutinib (marketed as BRUKINSA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>), an
inhibitor of Bruton&#146;s tyrosine kinase developed by BeiGene, Ltd. (&#147;BeiGene&#148;). This study arm completed the safety evaluation stage in patients with <FONT STYLE="white-space:nowrap">B-cell</FONT> malignancies and has expanded into
disease specific <FONT STYLE="white-space:nowrap">B-cell</FONT> malignancy cohorts. The evaluation of zandelisib in combination with zanubrutinib is conducted under a collaboration established with BeiGene in October 2018, pursuant to which the cost
of the combination trial is being equally shared, and each company is supplying its own investigational agent. We retain all commercial rights to zandelisib (subject to the KKC Commercialization Agreement) and BeiGene retains all commercial rights
to zanubrutinib. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Ongoing clinical trials also include Phase 1 and Phase 2 studies conducted by KKC evaluating zandelisib as a monotherapy in patients in Japan with
indolent <FONT STYLE="white-space:nowrap">B-cell</FONT> malignancies. The Phase 2 study is intended to support marketing authorization in Japan. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition to
other planned clinical studies sponsored by us, such as initiation of a Phase 2 study evaluating zandelisib plus venetoclax in patients with chronic lymphocytic leukemia (&#147;CLL&#148;), we also plan to support select investigator-initiated
studies, including one being conducted at the Cleveland Clinic evaluating zandelisib combined with standard of care in patients with newly diagnosed diffuse large <FONT STYLE="white-space:nowrap">B-cell</FONT> lymphoma (&#147;DLBCL&#148;). </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Phase 1b <FONT STYLE="white-space:nowrap">Multi-arm</FONT> Trial </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In May 2021, we reported updated data from the ongoing Phase 1b clinical trial evaluating zandelisib as a monotherapy and in combination with rituximab in patients with
r/r FL and other <FONT STYLE="white-space:nowrap">B-cell</FONT> malignancies as featured in poster discussions at the American Society of Clinical Oncology (&#147;ASCO&#148;) 2021 annual meeting. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Data were reported from 37 patients with r/r FL administered zandelisib 60 mg once daily for two <FONT STYLE="white-space:nowrap">28-day</FONT> cycles and then on an
intermittent schedule (&#147;IS&#148;) of once daily dosing for the first seven days of each subsequent <FONT STYLE="white-space:nowrap">28-day</FONT> cycle. The objective of this data presentation was to evaluate the safety, tolerability and
efficacy of zandelisib as monotherapy or in combination with rituximab in patients with FL who had disease progression within 24 months after initial chemoimmunotherapy (&#147;POD24&#148;) or disease progression beyond 24 months <FONT
STYLE="white-space:nowrap">(&#147;non-POD24&#148;).</FONT> </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The overall response rate in the 37 patients with r/r FL was 87%, with 27% achieving a complete
response. The overall response rate was 78% in 18 patients administered zandelisib as a monotherapy and 95% in 19 patients administered zandelisib in combination with rituximab. The overall response rate in nine evaluable patients with CLL,
previously reported separately, was 89%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Overall Response Rates </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>POD24<BR>n&nbsp;=&nbsp;22</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B><FONT STYLE="white-space:nowrap">NON-POD24</FONT><BR>n&nbsp;=&nbsp;15</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL&nbsp;FL<BR>n&nbsp;=&nbsp;37</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Overall response rate</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18&nbsp;(82%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14&nbsp;(93%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32&nbsp;(87%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Regimen</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Monotherapy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8/11&nbsp;(73%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6/7&nbsp;(86%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14/18&nbsp;(78%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Combination with rituximab</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/11&nbsp;(91%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8/8&nbsp;(100%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18/19 (95%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Prior lines of therapy</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">1 prior</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5/7 (71%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9/9&nbsp;(100%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14/16 (88%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT></FONT> 2
prior</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13/15&nbsp;(87%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5/6 (83%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18/21 (86%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>CR rate, n (%)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4 (18%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6 (40%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10 (27%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Median duration of response in 32 patients with FL who achieved an overall response, as reported in a poster presentation at the 16th International Conference on
Malignant Lymphoma, has not yet been reached, and median <FONT STYLE="white-space:nowrap">follow-up</FONT> was 16.9 months (range: 1.2 to 33.1 months). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Responses
appeared durable across both POD24 and <FONT STYLE="white-space:nowrap">non-POD24</FONT> groups, despite more heavily <FONT STYLE="white-space:nowrap">pre-treated</FONT> and refractory disease in the POD24 group. POD24 is defined as progression of
disease within 24 months of first-line chemo-immunotherapy. Patients with POD24 had more prior lines of treatment and more refractory disease. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Duration of Response: Follicular Lymphoma Patients </I></B></P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g236540g12v45.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Zandelisib was generally well-tolerated. The rate of drug related grade 3 adverse events of special interest (&#147;AESI&#148;),
those adverse caused by immune dysregulation, in the 37 patients with r/r FL was: diarrhea 5% (n=2); colitis 5% (n=2); rash 8% (n=3); alanine aminotransferase (&#147;ALT&#148;)/ aspartate aminotransferase (&#147;AST&#148;) elevation 8% (n=3) . The
discontinuation rate due to adverse events was 8% (n=3). </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Data from the arm of the Phase 1b study evaluating 20 patients receiving zandelisib in combination with
zanubrutinib was also reported in a poster session at the ASCO 2021 Annual Meeting. In this arm of the study two treatment dosing regimens were explored: Group A received zandelisib 60 mg, oral, daily continuously for eight weeks followed by days <FONT
STYLE="white-space:nowrap">1-7</FONT> of each subsequent <FONT STYLE="white-space:nowrap">28-day</FONT> cycle, and zanubrutinib, 160 mg oral, twice daily; Group B received zandelisib 60 mg, oral, daily on days
<FONT STYLE="white-space:nowrap">1-7</FONT> of each <FONT STYLE="white-space:nowrap">28-day</FONT> cycle starting Cycle 1 and zanubrutinib 80 mg, oral, twice daily. Group A enrolled a total of seven patients: one FL, three CLL, one MZL, one mantle
cell lymphoma (&#147;MCL&#148;), and one diffuse large <FONT STYLE="white-space:nowrap">B-cell</FONT> lymphoma/high grade <FONT STYLE="white-space:nowrap">B-cell</FONT> lymphoma (&#147;DLBCL/HGBCL&#148;). Group B enrolled a total of 13 patients:
seven FL, two CLL, one MZL, and three DLBCL/HGBCL. Treatment was continued until disease progression, intolerance or withdrawal of consent. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The ORR in all evaluable patients with r/r indolent <FONT STYLE="white-space:nowrap">B-cell</FONT> malignancies and
CLL was 100%. No response was noted in the two patients with DLBCL/HGBCL. Responses were durable with median follow up for all patients was 6.6 months (0.6 to 21.3 months) with the majority of responders still on treatment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Overall Response Rate </B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>EVALUABLE</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>n&nbsp;=&nbsp;18</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>FL<BR>(n&nbsp;=&nbsp;8)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>CLL/SLL<BR>(n&nbsp;=&nbsp;5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>MZL<BR>(n&nbsp;=&nbsp;2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>MCL<BR>(n&nbsp;=&nbsp;1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DLBCL/HGBCL<BR>(n = 2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">ORR*, n (%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8&nbsp;(100%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5&nbsp;(100%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2&nbsp;(100%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1&nbsp;(100%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0&nbsp;(0%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Group A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1&nbsp;(100%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3&nbsp;(100%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1&nbsp;(100%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1&nbsp;(100%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0&nbsp;(0%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Group B</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7&nbsp;(100%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2&nbsp;(100%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1&nbsp;(100%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0 (0%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0&nbsp;(0%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">*</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">CR/CRi in two of eight patients with FL (25%) and in two of five patients with CLL (40%). </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Imaging scans were taken at
months 3, 7, 13, and then every six months until disease progression. Response reported based on Lugano criteria and International Workshop on Chronic Lymphocytic Leukemia (&#147;iwCLL&#148;). Two of 20 patients (one in DLBCL and one in HGBCL) did
not have <FONT STYLE="white-space:nowrap">on-therapy</FONT> scans. One patient had clinical progressive disease (&#147;PD&#148;) and one patient had adverse events (&#147;AE&#148;) due to prior therapy and discontinued early. Median follow-up time
was 6.6 months for all patients (range 0.6 to 21.3 months), 3.6 months for Group A (range 0.6 to 21.3 months), and 6.6 months for Group B (range 1.9 to 14.1 months). </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Group B, which received zandelisib 60 mg orally, daily on days <FONT STYLE="white-space:nowrap">1-7</FONT> of each <FONT STYLE="white-space:nowrap">28-day</FONT> cycle
starting Cycle 1 and zanubrutinib 80 mg, orally, twice daily, was well tolerated across the various <FONT STYLE="white-space:nowrap">B-cell</FONT> malignancies in the completed part of the study. The combination administered on the optimized, Group
B, dosing regimen did not result in additive toxicity to each agent alone. One of the two patients with Grade 3 AST/ALT increases in Group B was successfully retreated and continued therapy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Treatment-Emergent Adverse Events of Special Interest </B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>GROUP&nbsp;A</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>GROUP&nbsp;B</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Grade <FONT STYLE="white-space:nowrap">3-4</FONT> AESI, n (%)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>(n&nbsp;=&nbsp;7)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>(n&nbsp;=&nbsp;13)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">ALT / ALT increased</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2&nbsp;(29%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2&nbsp;(15%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Rash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1&nbsp;(14%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0&nbsp;(0%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">CMV colitis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1&nbsp;(14%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0&nbsp;(0%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pneumonia</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*1&nbsp;(14%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0&nbsp;(0%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Diarrhea</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0&nbsp;(0%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0&nbsp;(0%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Atrial fibrillation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0&nbsp;(0%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0&nbsp;(0%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">*</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">1 DLBCL patient had several Grade 3 AEs on Day 1 attributed to prior therapy and discontinued treatment on Day 17. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
Phase 1b study is continuing to enroll expansion cohorts in r/r FL and r/r MCL to further evaluate the combination of zandelisib 60 mg administered on days <FONT STYLE="white-space:nowrap">1-7</FONT> starting Cycle 1 and zanubrutinib administered at
80 mg twice daily. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>TIDAL: A Phase 2 Trial Intended to Support Accelerated Approval of Marketing Applications </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">TIDAL is a global, open-label, Phase 2 trial evaluating zandelisib as a monotherapy across two study disease cohort: the first cohorts for the treatment of adults with
r/r FL and the second cohort for r/r MZL, in both cases after failure of at least two prior systemic therapies including chemotherapy with an alkylating agent and an anti-CD20 antibody. Subject to the results and discussions with the FDA, data from
each study arm are intended to be submitted to the FDA to support marketing applications for accelerated approval. The study is evaluating zandelisib administered once daily at 60 mg for two <FONT STYLE="white-space:nowrap">28-day</FONT> cycles and
then on an intermittent schedule of once daily dosing for the first seven days of each subsequent <FONT STYLE="white-space:nowrap">28-day</FONT> cycle (i.e., IS). The primary efficacy endpoint is the rate of objective responses to therapy and other
endpoints include duration of response and tolerability of zandelisib. The primary efficacy population sample size for r/r FL is 91 patients and the </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
primary efficacy population sample size for r/r MZL is 64 patients. Complete enrollment of the FL primary efficacy population of 91 patients for the evaluation of ORR and DOR was announced in
April 2021. The total study population in the FL arm is 121 patients to provide additional safety data for the registration application. The median age of patients with FL was 64 years old. Patients enrolled in the FL arm received a median of 3
prior lines of treatment (range: <FONT STYLE="white-space:nowrap">2-8).</FONT> <B></B>Enrollment in the MZL cohort is ongoing. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Efficacy. </B>The ORR in the 91
patients with r/r FL enrolled in the primary efficacy population was 70.3% (n=64), 95% CI=59.8, 79.5, as assessed by IRC after a minimum <FONT STYLE="white-space:nowrap">follow-up</FONT> of 6 months; the complete response rate was 35.2%, 95%
CI=25.4, 45.9. The ORR represents the primary endpoint of the TIDAL study. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of the data cutoff date, the data are not sufficiently mature to accurately estimate
the final DOR in the FL primary efficacy population, a secondary outcome measure of the TIDAL study. However, with a median <FONT STYLE="white-space:nowrap">follow-up</FONT> time for response of 8.4 months, the median DOR had not been reached. The
data cutoff date is approximately 6 months after the last patient in the primary efficacy population received their first dose of zandelisib. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Safety and
Tolerability. </B>Based upon interim data, zandelisib appeared generally well-tolerated in the total TIDAL study population through the data cutoff date. The safety data observed in TIDAL was consistent with data previously reported from the Phase
1B study (NCT02914938) evaluating zandelisib in patients with <FONT STYLE="white-space:nowrap">B-cell</FONT> malignancies as a single agent or in combination with rituximab (Rituxan<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>). </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of the data cutoff date, with a median follow up of 9.4 months&nbsp;(range: <FONT STYLE="white-space:nowrap">0.8-24)</FONT> in the total FL study population, the
incidence of Grade <FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT></FONT>3 Adverse Events of Special Interest (i.e., those adverse caused by immune dysregulation) were: 1.7% ALT/AST elevation, 1.7% colitis,
5% diarrhea, 2.5% mucositis, 0.8% pneumonitis, and 3.3% rash. The discontinuation rate due to any drug related adverse event in the group was 9.9%, also as of the data cutoff date. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A more complete report of the TIDAL data as of the data cutoff date will be submitted for presentation at upcoming scientific congresses in 2022. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>COASTAL: A Phase 3 Trial Intended to Support Full FDA and Global Marketing Authorizations </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">COASTAL is a global, open-label, randomized, <FONT STYLE="white-space:nowrap">two-arm</FONT> Phase 3 trial comparing zandelisib plus rituximab to standard of care
chemotherapy plus rituximab, in patients with r/r FL or MZL who received at least one prior line of therapy, which must have included an anti-CD20 monoclonal antibody in combination with chemotherapy or lenalidomide. COASTAL is expected to enroll
534 patients. Zandelisib will be administered once daily for two <FONT STYLE="white-space:nowrap">28-day</FONT> cycles followed by an intermittent schedule of once daily dosing for seven days of each subsequent
<FONT STYLE="white-space:nowrap">28-day</FONT> cycle for a total of 24 months, in combination with rituximab (&#147;R&#148;) in the first six months only. The control arm will consist of six cycles of the standard chemoimmunotherapy regimens <FONT
STYLE="white-space:nowrap">R-CHOP</FONT> or <FONT STYLE="white-space:nowrap">R-bendamustine,</FONT> with rituximab. The primary efficacy endpoint is progression-free survival; secondary endpoints include overall response rate, overall survival,
patient reported outcomes assessments, and safety and tolerability. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">COASTAL is intended to support full marketing applications in the U.S. and globally in r/r FL
and MZL patients who have received at least one prior line of treatment. COASTAL is also intended (subject to FDA agreement) to act as a confirmatory study for the potential U.S. accelerated approval of zandelisib based on the ongoing Phase 2 TIDAL
study evaluating patients with r/r FL and MZL patients who have received two or more prior lines of treatment. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Impact of
<FONT STYLE="white-space:nowrap">COVID-19</FONT> on the TIDAL and COASTAL Studies </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The extent to which the <FONT STYLE="white-space:nowrap">COVID-19</FONT>
pandemic will impact the progress of the zandelisib development program, including the enrollment and completion of the COASTAL and TIDAL studies, is subject to future developments, which are highly uncertain and cannot be predicted with confidence.
Currently, we believe that the integrity of the program and individual studies remains intact; however, the pandemic did have a negative impact on the rate of enrollment in the TIDAL study. The development program remains ongoing and is
</P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
continuing to enroll patients, although enrollment may potentially occur at a reduced rate. We will continue to closely monitor for potential negative impacts on the development program related
to the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. We will also continue efforts to be proactive in managing the impact from the pandemic, including various actions to communicate with sites and investigators, and making
accommodations to patients consistent with FDA guidance and guidance from other regulatory authorities, as we may deem appropriate. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Voruciclib: CDK Inhibitor
with CDK9 Inhibition in Phase 1 Studies </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Voruciclib is an orally administered CDK inhibitor differentiated by its potent in vitro inhibition of CDK9 in
addition to CDK6, 4 and 1. Voruciclib is being evaluated in a Phase 1b trial evaluating dose and schedule in patients with acute myeloid leukemia (&#147;AML&#148;) and <FONT STYLE="white-space:nowrap">B-cell</FONT> malignancies. Voruciclib is also
being evaluated in <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies to explore the potential synergistic activity in various solid tumor cancers of voruciclib in combination with drug-candidates that directly inhibit KRAS as well as
other targets in the RAS signaling pathway.</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Voruciclib Scientific Overview: Cell Cycle Signaling </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">CDK9 has important functions in cell cycle regulation, including the modulation of two therapeutic targets in cancer: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">CDK9 is a transcriptional regulator of the myeloid leukemia cell differentiation protein (&#147;MCL1&#148;), a member of
the family of anti-apoptotic proteins which, when elevated, may prevent the cell from undergoing cell death. Inhibition of CDK9 blocks the production of MCL1, which is an established resistance mechanism to the
<FONT STYLE="white-space:nowrap">B-cell</FONT> lymphoma (&#147;BCL2&#148;) inhibitor venetoclax (marketed as Venclexta<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>). </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">CDK9 is a transcriptional regulator of the MYC proto-oncogene protein (&#147;MYC&#148;) which regulates cell proliferation
and growth. Upregulation of MYC is implicated in many human cancers and is frequently associated with poor prognosis and unfavorable patient survival. CDK9, in addition to being a transcription factor for MYC, also decreases phosphorylation of MYC
protein that is implicated in stabilizing MYC in KRAS mutant cancers. Targeting MYC directly has historically been difficult, but CDK9 is a promising approach to target this oncogene. </P></TD></TR></TABLE>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Voruciclib: Inhibition of MCL1 </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In
<FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies voruciclib shows dose-dependent suppression of MCL1; in December 2017, a study of voruciclib published in the journal <I>Nature Scientific Reports</I> reported that the combination of
voruciclib plus the <FONT STYLE="white-space:nowrap">BCL-2</FONT> inhibitor venetoclax was capable of inhibiting two master regulators of cell survival, <FONT STYLE="white-space:nowrap">MCL-1</FONT> and <FONT STYLE="white-space:nowrap">BCL-2,</FONT>
and achieved synergistic antitumor effect in an aggressive subset of DLBCL <FONT STYLE="white-space:nowrap">pre-clinical</FONT> models. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Additionally, a peer
reviewed manuscript published in 2020 by Luedtke et al, concluded that the inhibition of CDK9 by voruciclib synergistically enhances cell death induced by the <FONT STYLE="white-space:nowrap">Bcl-2</FONT> selective inhibitor venetoclax in <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> models of acute myeloid leukemia. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The research presented suggests that voruciclib could be an attractive therapeutic
target for treating cancers in combination with venetoclax or other <FONT STYLE="white-space:nowrap">BCL-2</FONT> inhibitors. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Voruciclib: Inhibition of MYC
</I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">KRAS mutated cancers are frequently associated with overexpression of MYC, a transcription factor regulating cell proliferation and growth. CDK9 is a known
regulator of MYC transcription and a modulator of MYC protein phosphorylation. Data reported at the American Association for Cancer Research (&#147;AACR&#148;) Annual Meeting 2021 in <FONT STYLE="white-space:nowrap">pre-clinical</FONT> models
demonstrates that voruciclib: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Results in a rapid decrease in the phosphorylation of proteins that promote MYC transcription; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Rapidly decreases phosphorylation of MYC protein on Ser62, a site implicated in stabilizing MYC in KRAS mutant cancers;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Possesses single agent activity against multiple KRAS mutant cancer cell lines both <I>in vitro </I>and <I>in vivo;</I>
</P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Synergistically inhibits KRAS G12C mutant cancer cell lines in combination with KRAS G12C inhibitors, both <I>in vitro</I>
and <I>in vivo.</I> </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The research presented suggests that voruciclib could be an attractive therapeutic target for cancers driven by KRAS
mutations. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Clinical Program </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are evaluating patients with
hematological malignancies in a Phase 1b clinical trial evaluating the dose and schedule of voruciclib. The trial is initially intended to evaluate the dose and schedule of voruciclib as a monotherapy in patients with relapsed and refractory <FONT
STYLE="white-space:nowrap">B-cell</FONT> malignancies and AML after failure of prior standard therapies to determine the safety, preliminary efficacy and maximum tolerated dose. Once initial dose levels and schedules have been established, we plan
in parallel, subject to FDA agreement, to evaluate the dose and schedule of voruciclib in combination with a BCL2 inhibitor such as venetoclax to assess synergies and the opportunity for combination treatments, initially in patients with AML and
subsequently across multiple indications. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Preliminary data to date from the Phase 1b study evaluating voruciclib as a monotherapy at the doses studied demonstrates
that voruciclib has not been associated with drug related gastrointestinal toxicity or neutropenia. Also, favorable pharmacokinetics have been observed, including a half-life supporting
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">once-a-day</FONT></FONT> oral dosing and dose proportional <FONT STYLE="white-space:nowrap">C-max.</FONT> Our projections suggest that doses of
<FONT STYLE="white-space:nowrap">150-200</FONT> mg may be sufficient to achieve plasma concentrations sufficient to inhibit the molecular target. Early signs of biological activity have also been observed in patients with AML. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Voruciclib was also previously evaluated in more than 70 patients with solid tumors in multiple Phase 1 studies. The totality of the clinical data, along with data from
<FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies, suggests voruciclib&#146;s ability to inhibit its molecular target at a projected dose as low as 150 mg daily. In one clinical study, voruciclib was evaluated in combination with
vemurafenib (marketed as Zelboraf<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>) in nine patients with BRAF mutated advanced/inoperable malignant melanoma. Three of three BRAF/MEK naive patients achieved a response: two partial responses
and one complete response. In this study voruciclib was dosed at 150 mg daily plus vemurafenib 720 mg or 960 mg twice daily in <FONT STYLE="white-space:nowrap">28-day</FONT> cycles. The most common adverse events were fatigue, constipation,
diarrhea, arthralgia and headache. One instance of grade 3 fatigue was dose limiting and no serious adverse events related to voruciclib were reported. Other clinical studies evaluated voruciclib at doses up to 850 mg in patients with solid tumors,
demonstrating additional evidence of potential biologic activity and an adverse event profile generally consistent with other drugs in its class. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Impact of <FONT
STYLE="white-space:nowrap">COVID-19</FONT> on the Voruciclib Clinical Development Program </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">While the extent to which the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic will impact the progress of the voruciclib clinical development program, including the ongoing Phase 1b study, is subject to future developments, which are highly uncertain and cannot be
predicted with confidence, the study remains ongoing and is continuing to enroll patients; however, the rate of enrollment of patients has been negatively impacted by the pandemic. We will continue efforts to be proactive in managing the impact from
the pandemic, including various actions to communicate with sites and investigators, and making accommodations to patients consistent with FDA guidance as we may deem appropriate. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I><FONT STYLE="white-space:nowrap">ME-344:</FONT> Clinical Stage Mitochondrial Inhibitor with Combinatorial Potential </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">ME-344</FONT> is our novel and tumor selective, isoflavone-derived mitochondrial inhibitor drug candidate. It directly targets the
OXPHOS complex 1, a pathway involved in adenosine triphosphate (&#147;ATP&#148;) production in the mitochondria. <FONT STYLE="white-space:nowrap">ME-344</FONT> was studied in an investigator-initiated, multi-center, randomized clinical trial in
combination with the vascular endothelial growth factor (&#147;VEGF&#148;) inhibitor bevacizumab (marketed as Avastin&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>) in a total of 42 patients with human epidermal growth factor
receptor 2 (&#147;HER2&#148;) negative breast cancer. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I><FONT STYLE="white-space:nowrap">ME-344</FONT> Scientific Overview: Cancer Metabolism </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Tumor cells often display a high metabolic rate to support cell division and growth. This heightened metabolism requires a continual supply of energy in the form of
ATP. The two major sources of ATP are the specialized cellular organelles termed mitochondria and through the metabolism of carbohydrates, proteins and lipids. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><FONT
STYLE="white-space:nowrap">ME-344</FONT> was identified through a screen of more than 400 new chemical structures originally created based on the central design of naturally occurring plant isoflavones. We believe that some of these synthetic
compounds, including our drug candidate <FONT STYLE="white-space:nowrap">ME-344,</FONT> interact with specific mitochondrial enzyme targets, resulting in the inhibition of ATP generation. When these compounds interact with their target, a rapid
reduction in ATP occurs, which leads to a cascade of biochemical events within the cell and ultimately to cell death. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Clinical Program </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">ME-344</FONT> demonstrated evidence of single agent activity against refractory solid tumors in a Phase 1 trial, and in <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> studies tumor cells treated with <FONT STYLE="white-space:nowrap">ME-344</FONT> resulted in a rapid loss of ATP and cancer cell death. In addition to single agent activity, <FONT
STYLE="white-space:nowrap">ME-344</FONT> may also have significant potential in combination with anti-angiogenic therapeutics. In <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies, it was shown that one outcome of anti-angiogenics was to
reduce the rate of glycolysis in tumors as a mechanism to slow tumor growth. However, tumor metabolism was able to shift to mitochondrial metabolism for energy production to support continued tumor proliferation. In such cases of tumor plasticity in
the presence of treatment with anti-angiogenics, targeting the alternative metabolic source with <FONT STYLE="white-space:nowrap">ME-344</FONT> may open an important therapeutic opportunity. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Support for this combinatorial use of <FONT STYLE="white-space:nowrap">ME-344</FONT> was first published in the June 2016 edition of <I>Cell Reports</I>; <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> data from a collaboration with the Spanish National Cancer Research Centre in Madrid demonstrated mitochondria-specific effects of <FONT STYLE="white-space:nowrap">ME-344</FONT> in cancer cells,
including substantially enhanced anti-tumor activity when combined with agents that inhibit the activity of VEGF. These data demonstrating the potential anti-cancer effects of combining <FONT STYLE="white-space:nowrap">ME-344</FONT> with a VEGF
inhibitor due to an inhibition of both mitochondrial and glycolytic metabolism provided a basis for commencement of an investigator-initiated trial of <FONT STYLE="white-space:nowrap">ME-344</FONT> in combination with bevacizumab in HER2 negative
breast cancer patients. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Results published in the November 2019 issue of Clinical Cancer Research from a multicenter, investigator-initiated, randomized,
open-label, clinical trial that evaluated the combination of <FONT STYLE="white-space:nowrap">ME-344</FONT> and bevacizumab in 42 women with early HER2-negative breast cancer further support the combinatorial use of
<FONT STYLE="white-space:nowrap">ME-344</FONT> with anti-angiogenic therapeutics. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The primary objective of the trial was to show proof of <FONT
STYLE="white-space:nowrap">ME-344</FONT> biologic activity as measured by Ki67 reductions in the presence of the nuclear protein Ki67 (expression of which is strongly associated with tumor cell proliferation and growth) from days 0 to 28 compared to
the control group who received bevacizumab alone. Secondary objectives included determining whether <FONT STYLE="white-space:nowrap">ME-344</FONT> biologic activity correlates with vascular normalization. The data demonstrate significant biologic
activity in the <FONT STYLE="white-space:nowrap">ME-344</FONT> treatment group: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">In <FONT STYLE="white-space:nowrap">ME-344</FONT> treated patients, mean absolute Ki67 decreases were 13.3 compared to an
increase of 1.1 in the bevacizumab monotherapy group (P=0.01). </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">In <FONT STYLE="white-space:nowrap">ME-344</FONT> treated patients, mean relative Ki67 decreases were 23% compared to an
increase of 186% in the bevacizumab monotherapy group (P &lt; 0.01). </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The mean relative Ki67 reduction in patients experiencing vascular normalization in the
<FONT STYLE="white-space:nowrap">ME-344</FONT> treated patients was 33%, compared to an increase of 11.8% in normalized patients from the bevacizumab monotherapy group (P=0.09). Approximately <FONT STYLE="white-space:nowrap">one-third</FONT> of
patients in each arm had vascular normalization. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Treatment was generally well tolerated; three grade 3 adverse events of high blood pressure were
reported, two in the <FONT STYLE="white-space:nowrap">ME-344</FONT> arm and one in the bevacizumab monotherapy arm. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Results from our earlier, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human,</FONT></FONT> single-agent Phase 1 clinical trial of <FONT STYLE="white-space:nowrap">ME-344</FONT> in patients with refractory solid tumors were published in the
April&nbsp;1, 2015 issue of<I> Cancer</I>. The results indicated that eight of 21 evaluable patients (38%) treated with <FONT STYLE="white-space:nowrap">ME-344</FONT> achieved stable disease or better, including five who
</P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
experienced progression-free survival that was at least twice the duration of their last prior treatment before entry into the trial. In addition, one of these patients, a heavily <FONT
STYLE="white-space:nowrap">pre-treated</FONT> patient with small cell lung cancer, achieved a confirmed partial response and remained on study for two years. <FONT STYLE="white-space:nowrap">ME-344</FONT> was generally well tolerated at doses equal
to or less than 10 mg/kg delivered on a weekly schedule for extended durations. Treatment-related adverse events included nausea, dizziness and fatigue. Dose-limiting toxicities were observed at both the 15 mg/kg and 20 mg/kg dose levels, consisting
primarily of grade 3 peripheral neuropathy. We are planning to advance <FONT STYLE="white-space:nowrap">ME-344</FONT> in combination with the anti-angiogenic antibody bevacizumab in a Phase 2 study evaluating patients with relapsed colorectal
cancer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Corporate Information </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our principal executive offices are
located at 11455 El Camino Real, San Diego, CA 92130, and our phone number is (858) <FONT STYLE="white-space:nowrap">369-7100.</FONT> Our website is located at www.meipharma.com. Information on or accessible through our website is not part of, or
incorporated by reference into, this prospectus supplement, other than documents filed with the SEC that we incorporate by reference. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>THE OFFERING </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Common stock offered by us pursuant to this prospectus supplement </P></TD>
<TD>17,500,000 shares of common stock </TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Common stock outstanding after the offering (assuming no exercise of the underwriters&#146; option to purchase
additional shares) </P></TD>
<TD>130,178,498 shares of common stock<SUP STYLE="font-size:85%; vertical-align:top"> (1)</SUP> </TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Option to purchase additional shares </P></TD>
<TD>We have granted the underwriters an option to purchase up to 2,625,000 additional shares of our common stock. This option is exercisable, in whole or in part, for a period of 30 days from the date of this prospectus supplement.
</TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Use of proceeds </P></TD>
<TD>We intend to use a portion of the net proceeds from this offering, together with other available funds, to progress our clinical development programs, prepare for and support the commercial launch of zandelisib, subject to receiving FDA
marketing approval, and for other general corporate purposes. See &#147;Use of Proceeds&#148; on page <FONT STYLE="white-space:nowrap">S-17.</FONT> </TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Nasdaq Capital Market symbol </P></TD>
<TD>&#147;MEIP&#148; </TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Risk factors </P></TD>
<TD>This investment involves a high degree of risk. See &#147;Risk Factors&#148; beginning on page <FONT STYLE="white-space:nowrap">S-14</FONT> of this prospectus supplement, the risk factors beginning on page 22 of our Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> as filed with the Securities and Exchange Commission on September&nbsp;2, 2021, as well as the other information included in or incorporated by reference in this prospectus supplement and the accompanying base
prospectus for a discussion of risks you should consider carefully before making an investment decision. </TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Based on 112,678,498 shares of common stock outstanding as of September&nbsp;30, 2021. Excludes (i) 20,641,523 shares of our common stock subject to outstanding options, with exercise prices ranging from $1.21 to $6.47
per share, (ii) 16,058,985 shares of our common stock subject to outstanding warrants, with an exercise price of $2.54 per share, (iii)&nbsp;restricted stock units for 232,650 shares of common stock, (iv) 7,106,383 shares of our common stock
available for awards under our Amended and Restated 2008 Stock Omnibus Equity Compensation Plan, and (v) 1,772,000 shares of our common stock available for awards under our 2021 Inducement Plan, in each case as of September&nbsp;30, 2021.
</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">&nbsp;&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Unless otherwise stated, all information contained in this prospectus supplement assumes no exercise of the underwriters&#146; option to purchase up to 2,625,000 additional shares. </TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="supprom236540_4"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Any investment in our common stock involves a high degree of risk. In addition to the other information included or incorporated by reference in this prospectus
supplement and the accompanying base prospectus, you should carefully consider the important factors set forth under the heading &#147;Risk Factors&#148; starting on page 22 of our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT>
for the fiscal year ended June&nbsp;30, 2021, and in other reports we file with the SEC from time to time, which are incorporated herein by reference, before investing in our securities. For further details, see the sections entitled &#147;Where You
Can Find More Information&#148; and &#147;Incorporation of Certain Information by Reference&#148; in this prospectus supplement. </I></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Any of the risk factors set
forth below or referred to above could significantly and negatively affect our business, results of operations or financial condition, which may lower the trading price of our common stock. The risks referred to above are not the only ones that may
exist. Additional risks not currently known by us or that we deem immaterial may also impair our business operations. You may lose all or a part of your investment. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to our <FONT STYLE="white-space:nowrap">Pre-Clinical</FONT> and Clinical Data </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Final data from our <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and completed clinical trials may differ materially from reported interim data
from ongoing studies and trials. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">With the exception of our ORR data reported in the primary follicular lymphoma efficacy population of 91 patients, the
data reported by us on November&nbsp;30, 2021 with respect to our pivotal Phase 2 TIDAL study evaluating zandelisib as a single agent for the treatment of FL patients described above under &#147;Prospectus Summary&#148; provides an initial look at
the data as of the data cutoff date and is interim and subject to change as more patient data become available with longer follow up. This data is from an ongoing study, and the final data may differ materially from the data reported. Our <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> and clinical data, other information and procedures relating to this drug candidate may not be sufficient to support approval by the FDA or any other U.S. or foreign regulatory authority, or regulatory
interpretation of these data and procedures may be unfavorable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Securities Markets and Investment in our Stock </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The trading price of the shares of our common stock has been and may continue to be highly volatile and could decline in value and we may incur significant costs
from class action litigation. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The trading price of our common stock could be highly volatile in response to various factors, many of which are beyond our
control, including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">failure to successfully develop our drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">design, results and timing of clinical trials <FONT STYLE="white-space:nowrap">and&nbsp;pre-clinical&nbsp;studies;</FONT>
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">announcements of technological innovations by us or our competitors; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">new products introduced or announced by us or our competitors; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">changes in financial estimates by securities analysts; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">actual or anticipated variations in operating results; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">expiration or termination of licenses, research contracts or other collaboration agreements; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">conditions or trends in the regulatory climate and the biotechnology, pharmaceutical and genomics industries;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">instability in the stock market as a result of current or future domestic and global events; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">changes in the market valuations of similar companies; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the liquidity of any market for our securities; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">threatened or actual delisting of our common stock from a national stock exchange. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Equity markets in general, and the market for biotechnology and life sciences companies in particular, have experienced substantial price and volume fluctuations that
have often been unrelated or disproportionate to the operating performance of companies traded in those markets. In addition, changes in economic conditions in the U.S., Europe or globally, particularly in the context of current global events, could
impact upon our ability to grow profitably. Adverse economic changes are outside our control and may result in material adverse impacts on our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
business or our results of operations. These broad market and industry factors may materially affect the market price of shares of our common stock, regardless of our development and operating
performance. In the past, following periods of volatility in the market price of a company&#146;s securities, securities class-action litigation has often been instituted against that company. Such litigation, if instituted against us, could cause
us to incur substantial costs and divert management&#146;s attention and resources. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Future sales of our common stock, including common stock issued upon
exercise of outstanding warrants or options, may depress the market price of our common stock and cause stockholders to experience dilution. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The market
price of our common stock could decline as a result of sales of substantial amounts of our common stock in the public market, including upon exercise of outstanding warrants or stock options, and any subsequent sales of such shares. As of
September&nbsp;30, 2021, we had outstanding warrants issued in our May 2018 private placement exercisable to purchase 16,058,985 shares of common stock at an exercise price of $2.54 per share, which expire in May 2023. We also had outstanding
options to purchase 20,641,523 shares of common stock and restricted stock units for 232,650&nbsp;shares of common stock. We may seek additional capital through one or more additional equity transactions in the future; however, such transactions
will be subject to market conditions and there can be no assurance any such transactions will be completed. If we sell shares in the future, the prices at which we sell these future shares will vary, and these variations may be significant.
Stockholders, including investors in this offering, will experience significant dilution if we sell these future shares at prices significantly below the price at which such stockholders invested. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Investors in this offering will experience immediate and substantial dilution and may experience further dilution in the future. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The public offering price of the common stock offered pursuant to this prospectus supplement is substantially higher than the net tangible book value per share of our
common stock. Therefore, if you purchase shares of common stock in this offering, you will incur immediate and substantial dilution in the net tangible book value per share of common stock from the price per share that you pay for the common stock.
Furthermore, we expect that we will seek to raise additional capital from time to time in the future. Such financings may involve the issuance of equity and/or securities convertible into or exercisable or exchangeable for our equity securities. We
also expect to continue to utilize equity-based compensation. To the extent the warrants and options are exercised or we issue common stock, preferred stock, or securities such as warrants that are convertible into, exercisable or exchangeable for,
our common stock or preferred stock in the future, you may experience further dilution. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Because we do not intend to pay, and have not paid, any cash
dividends on our shares of common stock, our stockholders will not be able to receive a return on their shares unless the value of our common stock appreciates and they sell their shares. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have never paid or declared any cash dividends on our common stock, and we intend to retain any future earnings to finance the development and expansion of our
business. We do not anticipate paying any cash dividends on our common stock in the foreseeable future. Therefore, our stockholders will not be able to receive a return on their investment unless the value of our common stock appreciates and they
sell their shares. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We will have broad discretion over the use of the net proceeds from this offering and upon any exercise of outstanding warrants and
options. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We will have broad discretion to use the net proceeds to us from this offering and upon any exercise of outstanding warrants and options, and
investors in our stock will be relying on the judgment of our board of directors and management regarding the application of these proceeds. Although we expect to use a substantial portion of the net proceeds from this offering and upon any exercise
of the warrants and options for general corporate purposes and progression of our clinical trial programs, we have not allocated these net proceeds for specific purposes. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We are authorized to issue blank check preferred stock, which could adversely affect the holders of our common stock. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our amended and restated certificate of incorporation allows us to issue blank check preferred stock with rights potentially senior to those of our common stock without
any further vote or action by the holders of our common stock. The issuance of a class of preferred stock could decrease the amount of earnings and assets available for distribution to the holders of our common stock or could adversely affect the
rights and powers, including voting rights, of such holders. In certain circumstances, such issuance could have the effect of decreasing the market price of our shares, or making a change in control of the Company more difficult. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our executive officers and directors may sell shares of their stock, and these sales could adversely affect our
stock price. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Sales of our stock by our executive officers and directors, or the perception that such sales may occur, could cause the market price of our
common stock to decline or could make it more difficult for us to raise funds through the sale of equity in the future. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In connection with this offering, we have
entered into <FONT STYLE="white-space:nowrap">a&nbsp;lock-up&nbsp;agreement</FONT> for a period of 90 days following this offering and our directors and officers have entered <FONT STYLE="white-space:nowrap">into&nbsp;lock-up&nbsp;agreements</FONT>
for a period of 90 days following this offering, in each case, subject to certain exceptions. We and our directors and officers may be released from <FONT STYLE="white-space:nowrap">the&nbsp;lock-up&nbsp;prior</FONT> to the expiration of <FONT
STYLE="white-space:nowrap">the&nbsp;lock-up&nbsp;period</FONT> at the sole discretion of Jefferies LLC and Stifel, Nicolaus&nbsp;&amp; Company, Incorporated. See &#147;Underwriting.&#148; Upon expiration or earlier release of <FONT
STYLE="white-space:nowrap">the&nbsp;lock-up,&nbsp;we</FONT> and our directors and officers may sell shares into the market, either as part, or outside of trading plans under SEC <FONT STYLE="white-space:nowrap">Rule&nbsp;10b5-1,&nbsp;which</FONT>
could adversely affect the market price of shares of common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="supprom236540_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We estimate that the net proceeds from our sale of 17,500,000 shares of our common stock in this offering will be approximately $42,270,000 (or approximately
$48,685,500 if the underwriters&#146; option to purchase additional shares is exercised in full), after deducting underwriting discounts and commissions and estimated offering expenses payable by us. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We intend to use a portion of the net proceeds from this offering, together with other available funds, to progress our clinical development programs, prepare for and
support the commercial launch of zandelisib, subject to receiving FDA marketing approval, as well as for working capital and other general corporate purposes. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We
have not specifically identified the precise amounts we will spend on particular areas or the timing of these expenditures. The amounts actually expended for each purpose may vary significantly depending upon numerous factors, including the amount
and timing of the proceeds from this offering, the progress of our clinical trials and other product development activities. In addition, expenditures may also depend on the establishment of new collaborative arrangements with other partners, the
availability of other financing and other factors. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We anticipate that we will be required to raise substantial additional capital to continue to fund the clinical
development of our drug candidates. We expect to seek to raise additional capital through additional public or private financings, principally through equity issuances. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="supprom236540_6"></A>DILUTION </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our net tangible book value as of September&nbsp;30, 2021 was approximately $31.8&nbsp;million, or $0.28 per share of common stock. Net tangible book value per share
is equal to our total tangible assets minus total liabilities, all divided by the number of shares of common stock outstanding. After giving effect to the sale by us of 17,500,000 shares of our common stock offered by this prospectus supplement at
the public offering price of $2.60 per share, and after deducting the estimated offering commissions and estimated offering expenses payable by us, our adjusted net tangible book value as of September&nbsp;30, 2021 would have been $74.1 million, or
$0.57 per share of common stock. This represents an immediate increase in net tangible book value of approximately $0.29 per share to existing stockholders and an immediate dilution of approximately $2.03 per share to new investors purchasing our
common stock in this offering. The following table illustrates this calculation on a per share basis: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Public offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net tangible book value per share as of September&nbsp;30, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.28</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Increase per share attributable to new investors in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">As-adjusted&nbsp;net</FONT> tangible book value per share as of
September&nbsp;30, 2021, after giving effect to this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Dilution per share to new investors in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.03</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The number of shares of common stock shown above to be outstanding after this offering is based on 112,678,498 shares outstanding as of September&nbsp;30, 2021 and
excludes the following shares underlying outstanding securities convertible or exercisable for shares of common stock as of the date hereof: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">options to purchase 20,641,523&nbsp;shares of common stock at exercise prices from $1.21 to $6.47 per share, which expire
at various dates in calendar years 2021 through 2031; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">outstanding warrants to purchase 16,058,985 shares of our common stock. The warrants are fully vested, exercisable at a
price of $2.54 per share and expire in May 2023; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">restricted stock units for 232,650&nbsp;shares of common stock, which vest in July 2022. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To the extent outstanding warrants or options are exercised, there will be further dilution to new investors. In addition, to the extent we issue additional equity
securities in connection with future capital raising activities, our then-existing stockholders may experience dilution. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="supprom236540_7"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Subject to the terms and conditions set forth in the underwriting agreement, dated December&nbsp;1, 2021, between us and Jefferies LLC, Stifel, Nicolaus&nbsp;&amp;
Company, Incorporated and Wells Fargo Securities, LLC as the representatives of the underwriters named below, we have agreed to sell to the underwriters, and each of the underwriters has agreed, severally and not jointly, to purchase from us, the
respective number of shares of common stock shown opposite its name below: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>UNDERWRITER</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER&nbsp;OF<BR>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Jefferies LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,087,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Stifel, Nicolaus&nbsp;&amp; Company, Incorporated</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,337,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Wells Fargo Securities, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,800,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">LifeSci Capital LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,400,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">H.C. Wainwright &amp; Co., LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">875,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriting agreement provides that the obligations of the several underwriters are subject to certain conditions precedent such as the receipt by the underwriters
of officers&#146; certificates and legal opinions and approval of certain legal matters by their counsel. The underwriting agreement provides that the underwriters will purchase all of the shares of common stock if any of them are purchased. If an
underwriter defaults, the underwriting agreement provides that the purchase commitments of the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> underwriters may be increased or the underwriting agreement may be terminated. We have agreed to
indemnify the underwriters and certain of their controlling persons against certain liabilities, including liabilities under the Securities Act, and to contribute to payments that the underwriters may be required to make in respect of those
liabilities. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriters have advised us that, following the completion of this offering, they currently intend to make a market in the common stock as
permitted by applicable laws and regulations. However, the underwriters are not obligated to do so, and the underwriters may discontinue any market-making activities at any time without notice in their sole discretion. Accordingly, no assurance can
be given as to the liquidity of the trading market for the common stock, that you will be able to sell any of the common stock held by you at a particular time or that the prices that you receive when you sell will be favorable. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriters are offering the shares of common stock subject to their acceptance of the shares of common stock from us and subject to prior sale. The underwriters
reserve the right to withdraw, cancel or modify offers to the public and to reject orders in whole or in part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Commission and Expenses </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table shows the public offering price, the underwriting discounts and commissions that we are to pay the underwriters and the proceeds, before expenses,
to us in connection with this offering. Such amounts are shown assuming both no exercise and full exercise of the underwriters&#146; option to purchase additional shares. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PER SHARE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WITHOUT<BR>OPTION TO<BR>PURCHASE<BR>ADDITIONAL<BR>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WITH<BR>OPTION TO<BR>PURCHASE<BR>ADDITIONAL<BR>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WITHOUT<BR>OPTION TO<BR>PURCHASE<BR>ADDITIONAL<BR>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WITH OPTION<BR>TO PURCHASE<BR>ADDITIONAL<BR>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">45,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">52,325,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Underwriting discounts and commissions paid by us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,730,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,139,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Proceeds to us, before expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.444</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.444</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">42,770,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">49,185,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We estimate expenses payable by us in connection with this offering, other than the underwriting discounts and commissions referred to above, will be approximately
$500,000. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Listing </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our common stock
is listed on the Nasdaq Capital Market under the symbol &#147;MEIP.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Stamp Taxes </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If you purchase shares of common stock offered in this prospectus, you may be required to pay stamp taxes and other charges under the laws and practices of the country
of purchase, in addition to the offering price listed on the cover page of this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Option to Purchase Additional Shares </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have granted to the underwriters an option, exercisable for 30 days from the date of this prospectus, to purchase, from time to time, in whole or in part, up to an
aggregate of 2,625,000&nbsp;shares from us at the public offering price set forth on the cover page of this prospectus, less underwriting discounts and commissions. If the underwriters exercise this option, each underwriter will be obligated,
subject to specified conditions, to purchase a number of additional shares proportionate to that underwriter&#146;s initial purchase commitment as indicated in the table above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>No Sales of Similar Securities </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We and our officers and directors have
agreed, subject to specified exceptions, not to directly or indirectly: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">sell, offer, contract or grant any option to sell (including any short sale), pledge, transfer, establish an open
&#147;put equivalent position&#148; within the meaning of Rule <FONT STYLE="white-space:nowrap">16a-1(h)</FONT> under the Securities Exchange Act of 1934, as amended, or </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">otherwise dispose of any shares of common stock, options or warrants to acquire shares of common stock, or securities
exchangeable or exercisable for or convertible into shares of common stock currently or hereafter owned either of record or beneficially, or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">publicly announce an intention to do any of the foregoing, </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">for a period of 90 days after the date of this prospectus supplement without the prior written consent of Jefferies LLC and Stifel, Nicolaus&nbsp;&amp; Company,
Incorporated. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This restriction terminates after the close of trading of the common stock on and including the 90th day after the date of this prospectus
supplement. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Jefferies LLC and Stifel, Nicolaus&nbsp;&amp; Company, Incorporated may, in their sole discretion and at any time or from time to time before the
termination of the <FONT STYLE="white-space:nowrap">90-day</FONT> period release all or any portion of the securities subject to <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements. There are no existing agreements between the underwriters
and any of our officers and directors who will execute a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement, providing consent to the sale of shares prior to the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Stabilization </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriters have advised us that they may engage in
short sale transactions, stabilizing transactions, syndicate covering transactions or the imposition of penalty bids in connection with this offering. These activities may have the effect of stabilizing or maintaining the market price of the common
stock at a level above that which might otherwise prevail in the open market. Establishing short sales positions may involve either &#147;covered&#148; short sales or &#147;naked&#148; short sales. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">&#147;Covered&#148; short sales are sales made in an amount not greater than the underwriters&#146; option to purchase additional shares of our common stock in this
offering. The underwriters may close out any covered short position by either exercising their option to purchase additional shares of our common stock or purchasing shares of our common stock in the open market. In determining the source of shares
to close out the covered short position, the underwriters will consider, among other things, the price of shares available for purchase in the open market as compared to the price at which they may purchase shares through the option to purchase
additional shares. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">&#147;Naked&#148; short sales are sales in excess of the option to purchase additional shares of our common stock. The underwriters must close
out any naked short position by purchasing shares in the open market. A naked short </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the shares of our common stock in the open market after pricing that
could adversely affect investors who purchase in this offering. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A stabilizing bid is a bid for the purchase of shares of common stock on behalf of the underwriters
for the purpose of fixing or maintaining the price of the common stock. A syndicate covering transaction is the bid for or the purchase of shares of common stock on behalf of the underwriters to reduce a short position incurred by the underwriters
in connection with the offering. Similar to other purchase transactions, the underwriter&#146;s purchases to cover the syndicate short sales may have the effect of raising or maintaining the market price of our common stock or preventing or
retarding a decline in the market price of our common stock. As a result, the price of our common stock may be higher than the price that might otherwise exist in the open market. A penalty bid is an arrangement permitting the underwriters to
reclaim the selling concession otherwise accruing to a syndicate member in connection with the offering if the common stock originally sold by such syndicate member are purchased in a syndicate covering transaction and therefore have not been
effectively placed by such syndicate member. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Neither we nor any of the underwriters make any representation or prediction as to the direction or magnitude of any
effect that the transactions described above may have on the price of our common stock. The underwriters are not obligated to engage in these activities and, if commenced, any of the activities may be discontinued at any time. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriters may also engage in passive market making transactions in our common stock on The NASDAQ Capital Market in accordance with Rule 103 of Regulation M
during a period before the commencement of offers or sales of shares of our common stock in this offering and extending through the completion of distribution. A passive market maker must display its bid at a price not in excess of the highest
independent bid of that security. However, if all independent bids are lowered below the passive market maker&#146;s bid, that bid must then be lowered when specified purchase limits are exceeded. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Electronic Distribution </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A prospectus in electronic format may be made
available by <FONT STYLE="white-space:nowrap">e-mail</FONT> or on the web sites or through online services maintained by one or more of the underwriters or their affiliates. In those cases, prospective investors may view offering terms online and
may be allowed to place orders online. The underwriters may agree with us to allocate a specific number of shares of common stock for sale to online brokerage account holders. Any such allocation for online distributions will be made by the
underwriters on the same basis as other allocations. Other than the prospectus in electronic format, the information on the underwriters&#146; web sites and any information contained in any other web site maintained by any of the underwriters is not
part of this prospectus, has not been approved and/or endorsed by us or the underwriters and should not be relied upon by investors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Other Activities and
Relationships </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriters and certain of their respective affiliates are full service financial institutions engaged in various activities, which may
include securities trading, commercial and investment banking, financial advisory, investment management, investment research, principal investment, hedging, financing and brokerage activities. The underwriters and certain of their respective
affiliates have, from time to time, performed, and may in the future perform, various commercial and investment banking and financial advisory services for us and our affiliates, for which they received or will receive customary fees and expenses.
Stifel, Nicolaus&nbsp;&amp; Company, Incorporated is the sales agent under our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;at-the-market&#148;</FONT></FONT> equity offering program, pursuant to which it receives customary
fees. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the ordinary course of their various business activities, the underwriters and certain of their respective affiliates may make or hold a broad array of
investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers, and such investment and securities
activities may involve securities and/or instruments issued by us and our affiliates. If the underwriters or their respective affiliates have a lending relationship with us, they routinely hedge their credit exposure to us consistent with their
customary risk management policies. The underwriters and their respective affiliates may hedge such exposure by entering into transactions which consist of either the purchase of credit default swaps or the creation of short positions in our
securities or the securities of our affiliates, including potentially the common stock offered hereby. Any such short positions could adversely affect future trading prices of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
the common stock offered hereby. The underwriters and certain of their respective affiliates may also communicate independent investment recommendations, market color or trading ideas and/or
publish or express independent research views in respect of such securities or instruments and may at any time hold, or recommend to clients that they acquire, long and/or short positions in such securities and instruments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Notice to Prospective Investors in the European Economic Area </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In relation
to each Member State of the European Economic Area (each, a &#147;Relevant Member State&#148;), no offer of shares may be made to the public in that Relevant Member State other than: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">to any legal entity which is a qualified investor as defined in the Prospectus Directive; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">B.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">to fewer than 100 or, if the Relevant Member State has implemented the relevant provision of the 2010 PD Amending
Directive, 150, natural or legal persons (other than qualified investors as defined in the Prospectus Directive), as permitted under the Prospectus Directive, subject to obtaining the prior consent of the representatives; or </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">C.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">in any other circumstances falling within Article 3(2) of the Prospectus Directive, </P></TD></TR></TABLE>
<P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL">provided that no such offer of shares shall require the Company or the representatives to publish a prospectus pursuant to Article 3 of the Prospectus
Directive or supplement a prospectus pursuant to Article 16 of the Prospectus Directive. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Each person in a Relevant Member State who initially acquires any shares
or to whom any offer is made will be deemed to have represented, acknowledged and agreed that it is a &#147;qualified investor&#148; within the meaning of the law in that Relevant Member State implementing Article 2(1)(e) of the Prospectus
Directive. In the case of any shares being offered to a financial intermediary as that term is used in Article 3(2) of the Prospectus Directive, each such financial intermediary will be deemed to have represented, acknowledged and agreed that the
shares acquired by it in the offer have not been acquired on a <FONT STYLE="white-space:nowrap">non-discretionary</FONT> basis on behalf of, nor have they been acquired with a view to their offer or resale to, persons in circumstances which may give
rise to an offer of any shares to the public other than their offer or resale in a Relevant Member State to qualified investors as so defined or in circumstances in which the prior consent of the representatives has been obtained to each such
proposed offer or resale. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company, the representatives and their affiliates will rely upon the truth and accuracy of the foregoing representations,
acknowledgements and agreements. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus has been prepared on the basis that any offer of shares in any Relevant Member State will be made pursuant to an
exemption under the Prospectus Directive from the requirement to publish a prospectus for offers of shares. Accordingly, any person making or intending to make an offer in that Relevant Member State of shares which are the subject of the offering
contemplated in this prospectus may only do so in circumstances in which no obligation arises for the Company or any of the underwriters to publish a prospectus pursuant to Article 3 of the Prospectus Directive in relation to such offer. Neither the
Company nor the underwriters have authorized, nor do they authorize, the making of any offer of shares in circumstances in which an obligation arises for the Company or the underwriters to publish a prospectus for such offer. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For the purpose of the above provisions, the expression &#147;an offer to the public&#148; in relation to any shares in any Relevant Member State means the
communication in any form and by any means of sufficient information on the terms of the offer and the shares to be offered so as to enable an investor to decide to purchase or subscribe the shares, as the same may be varied in the Relevant Member
State by any measure implementing the Prospectus Directive in the Relevant Member State and the expression &#147;Prospectus Directive&#148; means Directive 2003/71/EC (including the 2010 PD Amending Directive, to the extent implemented in the
Relevant Member States) and includes any relevant implementing measure in the Relevant Member State and the expression &#147;2010 PD Amending Directive&#148; means Directive 2010/73/EU. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Notice to Prospective Investors in the United Kingdom </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, in the
United Kingdom, this document is being distributed only to, and is directed only at, and any offer subsequently made may only be directed at persons who are &#147;qualified investors&#148; (as defined in the Prospectus Directive)&nbsp;(i) who have
professional experience in matters relating to investments falling within Article 19 (5) of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the &#147;Order&#148;) and/or (ii)&nbsp;who are high net worth companies (or persons to whom it may otherwise
be lawfully communicated) falling within Article 49(2)(a) to (d)&nbsp;of the Order (all such persons together being referred to as &#147;relevant persons&#148;). This document must not be acted on or relied on in the United Kingdom by persons who
are not relevant persons. In the United Kingdom, any investment or investment activity to which this document relates is only available to, and will be engaged in with, relevant persons. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Notice to Prospective Investors in Switzerland </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The shares may not be
publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange (&#147;SIX&#148;) or on any other stock exchange or regulated trading facility in Switzerland. This document has been prepared without regard to the disclosure
standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or
regulated trading facility in Switzerland. Neither this document nor any other offering or marketing material relating to the shares or the offering may be publicly distributed or otherwise made publicly available in Switzerland. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Neither this document nor any other offering or marketing material relating to the offering, the Company, the shares have been or will be filed with or approved by any
Swiss regulatory authority. In particular, this document will not be filed with, and the offer of shares will not be supervised by, the Swiss Financial Market Supervisory Authority FINMA (FINMA), and the offer of shares has not been and will not be
authorized under the Swiss Federal Act on Collective Investment Schemes (&#147;CISA&#148;). The investor protection afforded to acquirers of interests in collective investment schemes under the CISA does not extend to acquirers of shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Notice to Prospective Investors in the Dubai International Financial Centre </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus supplement relates to an Exempt Offer in accordance with the Offered Securities Rules of the Dubai Financial Services Authority (&#147;DFSA&#148;). This
prospectus supplement is intended for distribution only to persons of a type specified in the Offered Securities Rules of the DFSA. It must not be delivered to, or relied on by, any other person. The DFSA has no responsibility for reviewing or
verifying any documents in connection with Exempt Offers. The DFSA has not approved this prospectus supplement nor taken steps to verify the information set forth herein and has no responsibility for the prospectus supplement. The shares to which
this prospectus supplement relates may be illiquid and/or subject to restrictions on their resale. Prospective purchasers of the shares offered should conduct their own due diligence on the shares. If you do not understand the contents of this
prospectus supplement you should consult an authorized financial advisor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Notice to Prospective Investors in Australia </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">No placement document, prospectus, product disclosure statement or other disclosure document has been lodged with the Australian Securities and Investments Commission
(&#147;ASIC&#148;), in relation to the offering. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus does not constitute a prospectus, product disclosure statement or other disclosure document under
the Corporations Act 2001 (the &#147;Corporations Act&#148;), and does not purport to include the information required for a prospectus, product disclosure statement or other disclosure document under the Corporations Act. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any offer in Australia of the shares may only be made to persons (the &#147;Exempt Investors&#148;) who are &#147;sophisticated investors&#148; (within the meaning of
section 708(8) of the Corporations Act), &#147;professional investors&#148; (within the meaning of section 708(11) of the Corporations Act) or otherwise pursuant to one or more exemptions contained in section 708 of the Corporations Act so that it
is lawful to offer the shares without disclosure to investors under Chapter 6D of the Corporations Act. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The shares applied for by Exempt Investors in Australia
must not be offered for sale in Australia in the period of 12 months after the date of allotment under the offering, except in circumstances where disclosure to investors under Chapter 6D of the Corporations Act would not be required pursuant to an
exemption under section 708 of the Corporations Act or otherwise or where the offer is pursuant to a disclosure document which complies with Chapter 6D of the Corporations Act. Any person acquiring shares must observe such Australian <FONT
STYLE="white-space:nowrap">on-sale</FONT> restrictions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus contains general information only and does not take account of the investment objectives, financial
situation or particular needs of any particular person. It does not contain any securities recommendations or financial product advice. Before making an investment decision, investors need to consider whether the information in this prospectus is
appropriate to their needs, objectives and circumstances, and, if necessary, seek expert advice on those matters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Notice to Prospective Investors in Hong Kong
</B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The securities have not been offered or sold and will not be offered or sold in Hong Kong, by means of any document, other than (a)&nbsp;to &#147;professional
investors&#148; as defined in the Securities and Futures Ordinance (Cap. 571) of Hong Kong and any rules made under that Ordinance; or (b)&nbsp;in other circumstances which do not result in the document being a &#147;prospectus&#148; as defined in
the Companies Ordinance (Cap. 32) of Hong Kong or which do not constitute an offer to the public within the meaning of that Ordinance. No advertisement, invitation or document relating to the securities has been or may be issued or has been or may
be in the possession of any person for the purposes of issue, whether in Hong Kong or elsewhere, which is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under the
securities laws of Hong Kong) other than with respect to securities which are or are intended to be disposed of only to persons outside Hong Kong or only to &#147;professional investors&#148; as defined in the Securities and Futures Ordinance and
any rules made under that Ordinance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Notice to Prospective Investors in Japan </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The securities have not been and will not be registered under the Financial Instruments and Exchange Law of Japan (Law No.&nbsp;25 of 1948, as amended) and,
accordingly, will not be offered or sold, directly or indirectly, in Japan, or for the benefit of any Japanese Person or to others for <FONT STYLE="white-space:nowrap">re-offering</FONT> or resale, directly or indirectly, in Japan or to any Japanese
Person, except in compliance with all applicable laws, regulations and ministerial guidelines promulgated by relevant Japanese governmental or regulatory authorities in effect at the relevant time. For the purposes of this paragraph, &#147;Japanese
Person&#148; shall mean any person resident in Japan, including any corporation or other entity organized under the laws of Japan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Notice to Prospective
Investors in Singapore </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any
other document or material in connection with the offer or sale, or invitation for subscription or purchase, of <FONT STYLE="white-space:nowrap">Non-CIS</FONT> Securities may not be circulated or distributed, nor may the <FONT
STYLE="white-space:nowrap">Non-CIS</FONT> Securities be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i)&nbsp;to an institutional investor
under Section&nbsp;274 of the Securities and Futures Act, Chapter 289 of Singapore (the &#147;SFA&#148;), (ii) to a relevant person pursuant to Section&nbsp;275(1), or any person pursuant to Section&nbsp;275(1A), and in accordance with the
conditions specified in Section&nbsp;275, of the SFA, or (iii)&nbsp;otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Where the <FONT STYLE="white-space:nowrap">Non-CIS</FONT> Securities are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant person which is: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole business of
which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary
of the trust is an individual who is an accredited investor, </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">securities (as defined in Section&nbsp;239(1) of the SFA) of that corporation or the
beneficiaries&#146; rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the <FONT STYLE="white-space:nowrap">Non-CIS</FONT> Securities pursuant to an
offer made under Section&nbsp;275 of the SFA except: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">to an institutional investor or to a relevant person defined in Section&nbsp;275(2) of the SFA, or to any person arising
from an offer referred to in Section&nbsp;275(1A) or Section&nbsp;276(4)(i)(B) of the SFA; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">where no consideration is or will be given for the transfer; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">where the transfer is by operation of law; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">as specified in Section&nbsp;276(7) of the SFA; or </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">as specified in Regulation 32 of the Securities and Futures (Offers of Investments) (Shares and Debentures) Regulations
2005 of Singapore. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Canada </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus supplement
constitutes an &#147;exempt offering document&#148; as defined in and for the purposes of applicable Canadian securities laws. No prospectus has been filed with any securities commission or similar regulatory authority in Canada in connection with
the offer and sale of the common stock. No securities commission or similar regulatory authority in Canada has reviewed or in any way passed upon this prospectus supplement or on the merits of the common stock and any representation to the contrary
is an offence. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Canadian investors are advised that this prospectus supplement has been prepared in reliance on section 3A3 of National Instrument <FONT
STYLE="white-space:nowrap">33-105</FONT> Underwriting Conflicts (&#147;NI <FONT STYLE="white-space:nowrap">33-105&#148;).</FONT> Pursuant to section 3A.3 of <FONT STYLE="white-space:nowrap">NI&nbsp;33-105,</FONT> this prospectus supplement is exempt
from the requirement that the Company and the underwriter(s) provide investors with certain conflicts of interest disclosure pertaining to &#147;connected issuer&#148; and/or &#147;related issuer&#148; relationships that may exist between the
Company and the underwriter(s) as would otherwise be required pursuant to subsection 2.1(1) of NI <FONT STYLE="white-space:nowrap">33-105.</FONT> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Resale
Restrictions </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The offer and sale of the common stock in Canada is being made on a private placement basis only and is exempt from the requirement that the
Company prepares and files a prospectus under applicable Canadian securities laws. Any resale of the common stock acquired by a Canadian investor in this offering must be made in accordance with applicable Canadian securities laws, which may vary
depending on the relevant jurisdiction, and which may require resales to be made in accordance with Canadian prospectus requirements, pursuant to a statutory exemption from the prospectus requirements, in a transaction exempt from the prospectus
requirements or otherwise under a discretionary exemption from the prospectus requirements granted by the applicable local Canadian securities regulatory authority. These resale restrictions may under certain circumstances apply to resales of the
common stock outside of Canada. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Representations of Purchasers </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Each
Canadian investor who purchases the common stock will be deemed to have represented to the Company and the underwriter(s) that the investor (i)&nbsp;is purchasing the common stock as principal, or is deemed to be purchasing as principal in
accordance with applicable Canadian securities laws, for investment only and not with a view to resale or redistribution; (ii)&nbsp;is an &#147;accredited investor&#148; as such term is defined in section 1.1 of National Instrument <FONT
STYLE="white-space:nowrap">45-106</FONT> Prospectus Exemptions or, in Ontario, as such term is defined in section 73.3(1) of the Securities Act (Ontario); and (iii)&nbsp;is a &#147;permitted client&#148; as such term is defined in section 1.1 of
National Instrument <FONT STYLE="white-space:nowrap">31-103</FONT> Registration Requirements, Exemptions and Ongoing Registrant Obligations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Taxation and
Eligibility for Investment </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any discussion of taxation and related matters contained in this prospectus supplement does not purport to be a comprehensive
description of all of the tax considerations that may be relevant to a Canadian investor when deciding to purchase the common stock and, in particular, does not a I dress any Canadian tax considerations. No representation or warranty is hereby made
as to the tax consequences to a resident, or deemed resident, of Canada of an investment in the common stock or with respect to the eligibility of the common stock for investment by such investor under relevant Canadian federal and provincial
legislation and regulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Rights of Action for Damages or Rescission </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Securities legislation in certain of the Canadian jurisdictions provides certain purchasers of securities pursuant to an offering memorandum (such as this prospectus
supplement), including where the distribution involves an &#147;eligible foreign security&#148; as such term is defined in Ontario Securities Commission Rule <FONT STYLE="white-space:nowrap">45-501</FONT> Ontario Prospectus and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
Registration Exemptions and in Multilateral Instrument <FONT STYLE="white-space:nowrap">45-107</FONT> Listing Representation and Statutory Rights of Action Disclosure Exemptions, as applicable,
with a remedy for damages or rescission, or both, in addition to any other rights they may have at law, where the offering memorandum, or other offering document that constitutes an offering memorandum, and any amendment thereto, contains a
&#147;misrepresentation&#148; as defined under applicable Canadian securities laws. These remedies, or notice with respect to these remedies, must be exercised or delivered, as the case may be, by the purchaser within the time limits prescribed
under, and are subject to limitations and defenses under, applicable Canadian securities legislation. In addition, these remedies are in addition to and without derogation from any other right or remedy available at law to the investor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Language of Documents </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon receipt of this document, each Canadian investor
hereby confirms that it has expressly requested that all documents evidencing or relating in any way to the sale of the securities described herein (including for greater certainty any purchase confirmation or any notice) be drawn up in the English
language only. <I>Par la reception de ce document, chaque investisseur Canadien confirme par les presentes qu&#146;il a expressement exige que tour les documents faisant foi ou se rapportant de quelque maniere que ce soit a la vente des valeurs
mobilieres decrites aux presences (incluant, pour plus de certitude, toute confirmation d&#146;achat ou tout avis) soient rediges en anglais seulement.</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="supprom236540_8"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The validity of the issuance of the securities offered hereby will be passed upon for us by Morgan, Lewis&nbsp;&amp; Bockius LLP, New York, New York. Goodwin Procter
LLP, New York, New York, is acting as counsel for the underwriters. Certain partners of Morgan, Lewis&nbsp;&amp; Bockius LLP own a number of shares of our common stock which represent less than 0.1% of the total outstanding common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="supprom236540_9"></A>EXPERTS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The financial statements as of June 30, 2021 and 2020, and for each of the three years in the period ended June&nbsp;30, 2021, incorporated by reference in this
prospectus supplement, have been so incorporated in reliance on the report of BDO USA, LLP, an independent registered public accounting firm, incorporated herein by reference, given on the authority of said firm as experts in auditing and
accounting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="supprom236540_10"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public over the Internet at
the SEC&#146;s website at http://www.sec.gov. The SEC&#146;s website contains reports, proxy and information statements and other information regarding issuers, such as us, that file electronically with the SEC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="supprom236540_11"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The SEC allows us to &#147;incorporate by reference&#148; into this prospectus supplement the information we have filed with the SEC. The information we incorporate by
reference into this prospectus supplement is an important part of this prospectus supplement. Any statement in a document we incorporate by reference into this prospectus supplement or the accompanying base prospectus will be considered to be
modified or superseded to the extent a statement contained in this prospectus supplement or any other subsequently filed document that is incorporated by reference into this prospectus supplement modifies or supersedes that statement. The modified
or superseded statement will not be considered to be a part of this prospectus supplement or accompanying base prospectus, as applicable, except as modified or superseded. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We incorporate by reference into this prospectus supplement the information contained in the documents listed below, which is considered to be a part of this prospectus
supplement: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1262104/000095017021001655/meip-20210630.htm">Form
 <FONT STYLE="white-space:nowrap">10-K</FONT></A> for the fiscal year ended June&nbsp;30, 2021, filed with the SEC on September&nbsp;2, 2021; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our Quarterly Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1262104/000095017021004063/meip-20210930.htm">Form
 <FONT STYLE="white-space:nowrap">10-Q</FONT></A> for the quarterly period ended September&nbsp;30, 2021, filed with the SEC on November&nbsp;10, 2021; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1262104/000119312521237802/d204661d8k.htm">August&nbsp;5,
 2021</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1262104/000119312521337594/d261318d8k.htm">November<U></U>&nbsp;
23, 2021</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1262104/000119312521342891/d205347d8k.htm">November&nbsp;30, 2021</A>; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the information specifically incorporated by reference into our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1262104/000095017021001655/meip-20210630.htm">Form
 <FONT STYLE="white-space:nowrap">10-K</FONT></A> for the year ended June&nbsp;30, 2021 from our definitive proxy statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1262104/000119312521311264/d236296ddef14a.htm">Schedule 14A</A> (other
than information furnished rather than filed), which was filed with the SEC on October&nbsp;28, 2021; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the description of our common stock contained in the Registration Statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1262104/000095012303013241/y92081ae8va12g.txt">Form
 <FONT STYLE="white-space:nowrap">8-A</FONT></A> filed on November&nbsp;26, 2003 and any further amendment or report filed thereafter for the purpose of updating such description. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We also incorporate by reference all documents filed pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this prospectus supplement and
prior to the termination of this offering; provided, however, that we are not incorporating any information furnished under Item 2.02 or Item 7.01 of any current report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> we may subsequently file.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Statements made in this prospectus supplement or the accompanying base prospectus or in any document incorporated by reference in this prospectus supplement or the
accompanying base prospectus as to the contents of any contract or other document referred to herein or therein are not necessarily complete, and in each instance reference is made to the copy of such contract or other document filed as an exhibit
to the documents incorporated by reference, each such statement being qualified in all material respects by such reference. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">You may request a copy of these
filings, at no cost, by writing or telephoning us at the following address: </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">MEI Pharma, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">11455 El Camino Real, </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">San Diego, CA 92130 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Tel: (858) <FONT STYLE="white-space:nowrap">369-7100</FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Attn: Investor
Relations </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Copies of these filings are also available, without charge, through the &#147;Investors&#148; section of our website (www.meipharma.com) as soon as
reasonably practicable after they are filed electronically with the SEC. The information contained on our website is not a part of this prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>$200,000,000 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g236540g63p02.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>MEI PHARMA, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Preferred
Stock </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Warrants </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may offer up
to $200,000,000 aggregate dollar amount of our common stock, preferred stock and warrants to purchase our common stock or preferred stock from time to time in one or more offerings. This prospectus provides you with a general description of the
securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may offer these securities at prices and on terms to be set forth in one or more supplements to this prospectus. These
securities may be offered directly, through agents on our behalf or through underwriters or dealers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is traded on the
Nasdaq Capital Market under the symbol &#147;MEIP.&#148; On May&nbsp;18, 2020, the closing price of our common stock on the Nasdaq Capital Market was $2.94&nbsp;per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:12pt; font-family:Times New Roman"><B>An investment in our securities involves significant risks. See &#147;<A HREF="#toc236540_3">Risk Factors</A>&#148; on page&nbsp;3 of this
prospectus and in any applicable prospectus supplement and in the documents incorporated by reference in this prospectus for a discussion of factors you should carefully consider before deciding to purchase our securities. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or
passed upon the adequacy of this prospectus. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus
is May&nbsp;18, 2020. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="98%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc236540_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc236540_2">SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc236540_3">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc236540_4">CAUTIONARY STATEMENT ABOUT FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc236540_5">SECURITIES OFFERED BY THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc236540_6">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc236540_7">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc236540_8">DESCRIPTION OF SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc236540_9">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc236540_10">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc236540_11">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc236540_12">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc236540_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we have indicated otherwise, references in this prospectus to &#147;MEI Pharma,&#148; &#147;we,&#148; &#147;us&#148; and
&#147;our&#148; or similar terms are to MEI Pharma, Inc., a Delaware corporation. References in this prospectus to &#147;FDA&#148; refer to the United States Food and Drug Administration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement that we filed with the Securities and Exchange Commission, or SEC, utilizing a
&#147;shelf&#148; registration statement. This prospectus provides you with a general description of the securities we may offer. We will describe the specific terms of those securities, as necessary, in supplements that we attach to this prospectus
for each offering. Each supplement will also contain specific information about the terms of the offering it describes. The supplements may also add to, update or change information contained in this prospectus. In addition, as we describe in the
sections entitled &#147;Incorporation of Certain Information by Reference&#148; and &#147;Where You Can Find More Information,&#148; we have filed and plan to continue to file other documents with the SEC that contain information about us. Before
you decide whether to invest in our securities, you should read this prospectus, the supplement that further describes the offering of those securities and the information we otherwise file with the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The registration statement that contains this prospectus, including the exhibits to the registration statement, contains additional
information about us and the securities being offered under this prospectus. You should read the registration statement and the accompanying exhibits for further information. The registration statement and exhibits can be read and are available to
the public over the Internet at the SEC&#146;s website at http: //www.sec.gov. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>You should rely only on the information contained or
incorporated by reference in this prospectus and in any prospectus supplement. We have not authorized any person to provide any information or make any statement that differs from what is contained in this prospectus. If any person does make a
statement that differs from what is in this prospectus, you should not rely on it. This prospectus is not an offer to sell, nor is it a solicitation of an offer to buy, these securities in any state in which the offer or sale is not permitted. The
information in this prospectus is accurate as of its date, but the information may change after that date. You should not assume that the information in this prospectus is accurate as of any date after its date. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc236540_2"></A>SUMMARY </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Company </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a late-stage pharmaceutical company
focused on leveraging our extensive development and oncology expertise to identify and advance new therapies intended to meaningfully improve the treatment of cancer. Our portfolio of drug candidates contains four clinical-stage candidates,
including one candidate in an ongoing Phase 3 global registration trial and another candidate in an ongoing Phase 2 clinical trial that we intend to submit to the U.S. Food and Drug Administration (&#147;FDA&#148;) to support accelerated approval of
a marketing application. Our common stock is listed on the NASDAQ Capital Market under the symbol &#147;MEIP&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our approach to building our pipeline
is to license promising cancer agents and build value in programs through development, commercialization and strategic partnerships, as appropriate. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our principal executive offices
are located at 3611 Valley Centre Drive, Suite 500, San Diego, CA 92130, and our phone number is (858) <FONT STYLE="white-space:nowrap">369-7100.</FONT> </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc236540_3"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any investment in our securities involves a high degree of risk. In addition to the other information included or incorporated by reference in
this prospectus and any accompanying prospectus supplement, you should carefully consider the important factors set forth under the heading &#147;Risk Factors&#148; in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the
fiscal year ended June&nbsp;30, 2019, our Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended March&nbsp;31, 2020, and in our subsequent annual reports on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and
in other reports we file with the SEC from time to time, which are incorporated herein by reference, before investing in our securities. Any of the risk factors referred to above could significantly and negatively affect our business, results of
operations or financial condition, which may lower the trading price of our common stock. The risks referred to above are not the only ones that may exist. Additional risks not currently known by us or that we deem immaterial may also impair our
business operations. You may lose all or a part of your investment. For further details, see the sections entitled &#147;Where You Can Find More Information&#148; and &#147;Incorporation of Certain Information by Reference.&#148; </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc236540_4"></A>CAUTIONARY STATEMENT ABOUT FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus and the documents incorporated by reference herein include forward-looking statements within the meaning of Section&nbsp;27A
of the Securities Act of 1933, as amended (the &#147;Securities Act&#148;) and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;). All statements other than statements of historical facts contained in
this prospectus and in the documents incorporated by reference herein, including statements regarding the future financial position, business strategy and plans and objectives of management for future operations, are forward-looking statements. The
words &#147;believe,&#148; &#147;may,&#148; &#147;will,&#148; &#147;estimate,&#148; &#147;continue,&#148; &#147;anticipate,&#148; &#147;intend,&#148; &#147;should,&#148; &#147;plan,&#148; &#147;expect,&#148; and similar expressions, as they relate
to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on current expectations and projections about future events and financial trends that we believe may affect our financial condition,
results of operations, business strategy and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, without limitation, those described in &#147;Risk Factors&#148; and elsewhere
in this prospectus and the documents incorporated by reference herein, including, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs and delays in our clinical development programs, including delays in patient enrollment relating to the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic, and/or receipt of FDA or other required foreign and domestic governmental or regulatory approvals, or the failure to obtain such approvals, for our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to obtain required additional financing or financing available to us on acceptable terms, or at
all, whether as a result of weaknesses in the capital markets or otherwise, which may cause us to delay, scale-back or eliminate plans related to development of our drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Kyowa Kirin Company (&#147;KKC&#148;), Helsinn Healthcare SA (&#147;Helsinn&#148;) and other parties with which
we have entered into collaboration, license, development and/or commercialization agreements may not satisfy their obligations under the agreements which could impact future revenues; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our payment obligations under the Presage Biosciences, Inc. License Agreement and the S*Bio Purchase Agreement,
which may reduce our cash available for other development efforts, and other obligations and risks related to the Presage License Agreement and the S*Bio Purchase Agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical studies by their nature typically have a high level of risk and may not produce successful results;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the results of <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and completed clinical trials are not
necessarily predictive of future results, and our current drug candidates may not have favorable results in later studies or trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to maintain or enter into, and the risks resulting from our dependence upon, contractual
arrangements necessary for the clinical development, manufacture, commercialization, marketing, sales and distribution of our product candidates; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA&#146;s interpretation and our interpretation of data from preclinical and clinical studies may differ
significantly; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our failure to successfully commercialize our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pricing regulations, third-party reimbursement practices and healthcare reform initiatives;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the failure of any products to gain market acceptance; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our reliance on third parties to conduct our clinical trials and manufacture our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to control the costs of manufacturing our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our reliance on acquisitions or licenses from third parties to expand our pipeline of drug candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">competition and competitive factors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and
intellectual property to operate our business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to operate our business without infringing the patents and proprietary rights of others;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs stemming from our defense against third party intellectual property infringement claims;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our exposure to potential product liability claims and other claims may exceed our insurance limits;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to attract and retain key employees; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">technological changes; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cybersecurity; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general economic conditions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">government regulation generally; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in industry practice; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">one-time</FONT> events. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These risks are not exhaustive. Other sections of this report and our other filings with the SEC include additional factors which could
adversely impact our business and financial performance. Moreover, we operate in a very competitive and rapidly changing environment. There is substantial uncertainty regarding the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> on
our business, industry, global economic conditions and government policy. New risk factors emerge from time to time and it is not possible for us to predict all risk factors, nor can we assess the impact of all factors on our business or the extent
to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should not rely upon forward looking statements as predictions of future events. We cannot assure you that the events and circumstances
reflected in the forward looking statements will be achieved or occur. Although we believe that the expectations reflected in the forward looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or
achievements. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc236540_5"></A>SECURITIES OFFERED BY THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Using this prospectus, we may offer from time to time, in one or more series, together or separately, at prices and terms to be determined at
the time of offering: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">shares of common stock, $0.00000002 par value; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">shares of preferred stock, $0.01 par value; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">warrants to purchase shares of common stock or preferred stock. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares of preferred stock may be convertible into or exchangeable for shares of our
common stock or preferred stock issued by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See &#147;Description of Securities&#148; for a description of the terms of the common
stock, preferred stock and warrants. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc236540_6"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we expect to use a substantial portion of the net proceeds from the sale of securities under this prospectus for general corporate
purposes, including to progress our clinical trial programs, we have not allocated these net proceeds for specific purposes. If, as of the date of any prospectus supplement, we have identified any additional use for the net proceeds, we will
describe them in the prospectus supplement. The amount of securities offered from time to time pursuant to this prospectus and any prospectus supplement, and the precise amount of the net proceeds we will receive from the sale of such securities, as
well as the timing of receipt of those proceeds, will depend upon our funding requirements. If we elect at the time of an issuance of securities to make different or more specific uses of the proceeds than as set forth herein, we will describe those
uses in the applicable prospectus supplement. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc236540_7"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may sell the securities included in this prospectus (i)&nbsp;through agents, (ii)&nbsp;through underwriters, (iii)&nbsp;through dealers,
(iv)&nbsp;directly to a limited number of purchasers or to a single purchaser, or (v)&nbsp;through a combination of any such methods of sale. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The distribution of the securities may be effected from time to time in one or more transactions, including block transactions and
transactions on the Nasdaq Capital Market or any other organized market where the securities may be traded: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at a fixed price or at final prices, which may be changed; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at market prices prevailing at the time of sale; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at prices related to such prevailing market prices; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at negotiated prices. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Offers to purchase securities may be solicited directly by us, or by agents designated by us, from time to time. Any such agent, which may be
deemed to be an underwriter as that term is defined in the Securities Act, as amended, involved in the offer or sale of the securities in respect of which this prospectus is delivered will be named, and any commissions payable by us to such agent
will be set forth, in the applicable prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an underwriter is, or underwriters are, utilized in the offer and sale of
securities in respect of which this prospectus and the applicable prospectus supplement are delivered, we will execute an underwriting agreement with such underwriter(s) for the sale to it or them and the name(s) of the underwriter(s) and the terms
of the transaction, including any underwriting discounts and other items constituting compensation of the underwriters and dealers, if any, will be set forth in such prospectus supplement, which will be used by the underwriter(s) to make resales of
the securities in respect of which this prospectus and such prospectus supplement are delivered to the public. The securities will be acquired by the underwriters for their own accounts and may be resold from time to time in one or more
transactions, including negotiated transactions, at a fixed public offering price or at varying prices determined at the time of sale. Any initial public offering price and any discounts or concessions allowed or reallowed or paid to dealers may be
changed from time to time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a dealer is utilized in the sale of the securities in respect of which this prospectus is
delivered, we will sell such securities to the dealer, as principal. The dealer may then resell such securities to the public at varying prices to be determined by such dealer at the time of resale. The name of the dealer and the terms of the
transaction will be identified in the applicable prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an agent is used in an offering of securities being offered by
this prospectus, the agent will be named, and the terms of the agency will be described, in the applicable prospectus supplement relating to the offering. Unless otherwise indicated in the prospectus supplement, an agent will act on a best efforts
basis for the period of its appointment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If indicated in the applicable prospectus supplement, we will authorize underwriters or their
other agents to solicit offers by certain institutional investors to purchase securities from us pursuant to contracts providing for payment and delivery at a future date. Institutional investors with which these contracts may be made include
commercial and savings banks, insurance companies, pension funds, investment companies, educational and charitable institutions and others. In all cases, these purchasers must be approved by us. The obligations of any purchaser under any of these
contracts will not be subject to any conditions except that (a)&nbsp;the purchase of the securities must not at the time of delivery be prohibited under the laws of any jurisdiction to which that purchaser is subject, and (b)&nbsp;if the securities
are also being sold to underwriters, we must have sold to these underwriters the securities not subject to delayed delivery. Underwriters and other agents will not have any responsibility in respect of the validity or performance of these contracts.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of the underwriters, dealers or agents utilized by us in any offering hereby may be customers of, including borrowers from,
engage in transactions with, and perform services for us or one or more of our affiliates in the ordinary course of business. Underwriters, dealers, agents and other persons may be entitled, under agreements which may be entered into with us, to
indemnification against certain civil liabilities, including liabilities under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until the distribution of the
securities is completed, rules of the SEC may limit the ability of the underwriters and certain selling group members, if any, to bid for and purchase the securities. As an exception to these rules, the representatives of the underwriters, if any,
are permitted to engage in certain transactions that stabilize the price of the securities. Such transactions may consist of bids or purchases for the purpose of pegging, fixing or maintaining the price of the securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If underwriters create a short position in the securities in connection with the offering thereof (in other words, if they sell more
securities than are set forth on the cover page of the applicable prospectus supplement), the representatives of such underwriters may reduce that short position by purchasing securities in the open market. Any such representatives also may elect to
reduce any short position by exercising all or part of any over-allotment option described in the applicable prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any
such representatives also may impose a penalty bid on certain underwriters and selling group members. This means that if the representatives purchase securities in the open market to reduce the underwriters&#146; short position or to stabilize the
price of the securities, they may reclaim the amount of the selling concession from the underwriters and selling group members who sold those shares as part of the offering thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, purchases of a security for the purpose of stabilization or to reduce a syndicate short position could cause the price of the
security to be higher than it might otherwise be in the absence of such purchases. The imposition of a penalty bid might have an effect on the price of a security to the extent that it was to discourage resales of the security by purchasers in the
offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither we nor any of the underwriters, if any, makes any representation or prediction as to the direction or magnitude of any
effect that the transactions described above may have on the price of the securities. In addition, neither we nor any of the underwriters, if any, makes any representation that the representatives of the underwriters, if any, will engage in such
transactions or that such transactions, once commenced, will not be discontinued without notice. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The anticipated date of delivery of the securities offered by this prospectus will be
described in the applicable prospectus supplement relating to the offering. The securities offered by this prospectus may or may not be listed on a national securities exchange or a foreign securities exchange. We cannot give any assurances that
there will be a market for any of the securities offered by this prospectus and any prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will bear costs relating to
all of the securities being registered under this prospectus, other than underwriters&#146; discounts and commissions. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc236540_8">
</A>DESCRIPTION OF SECURITIES </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Securities We May Offer Under this Prospectus </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For a description of our
common stock, please see the Description of Capital Stock of MEI Pharma, Inc. filed as Exhibit 4.3 to Amendment No.&nbsp;1 to our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended June&nbsp;30, 2019, filed
with the SEC on December&nbsp;6, 2019, and any future description of capital stock filed thereafter for the purpose of updating such description. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The material terms of
any series of preferred stock that we offer through a prospectus supplement will be described in that prospectus supplement. Our board of directors is authorized to provide for the issuance of blank check preferred stock in one or more series with
designations as may be stated in the resolution or resolutions providing for the issue of such preferred shares. At the time that any series of our preferred stock is authorized, our board of directors will fix the dividend rights, any conversion
rights, any voting rights, redemption provisions, liquidation preferences and any other rights, preferences, privileges and restrictions of that series, as well as the number of shares constituting that series and their designation. Our board of
directors could, without stockholder approval, cause us to issue preferred stock which has voting, conversion and other rights that could adversely affect the holders of our common stock or make it more difficult to effect a change in control. Our
preferred stock could be used to dilute the share ownership of persons seeking to obtain control of us and thereby hinder a possible takeover attempt which, if our stockholders were offered a premium over the market value of their shares, might be
viewed as being beneficial to our stockholders. In addition, our preferred stock could be issued with voting, conversion and other rights and preferences which would adversely affect the voting power and other rights of holders of our common stock.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Warrants </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue warrants to
purchase our common stock or preferred stock. Warrants may be issued independently or together with any other securities and may be attached to, or separate from, such securities. Each series of warrants will be issued under a separate warrant
agreement to be entered into between us and a warrant agent. The terms of any warrants to be issued and a description of the material provisions of the applicable warrant agreement will be set forth in the applicable prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The applicable prospectus supplement will describe the following terms of any warrants in respect of which this prospectus is being delivered:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title of such warrants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the aggregate number of such warrants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the price or prices at which such warrants will be issued; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the currency or currencies, in which the price of such warrants will be payable; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the securities purchasable upon exercise of such warrants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the price at which and the currency or currencies in which the securities or other rights purchasable upon
exercise of such warrants may be purchased; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date on which the right to exercise such warrants shall commence and the date on which such right shall
expire; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the minimum or maximum amount of such warrants which may be exercised at any one time;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the designation and terms of the securities with which such warrants are issued and the number of
such warrants issued with each such security; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the date on and after which such warrants and the related securities will be separately
transferable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">information with respect to book-entry procedures, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, a discussion of any material United States federal income tax considerations; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other terms of such warrants, including terms, procedures and limitations relating to the exchange and
exercise of such warrants. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Description of Share Capital </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are authorized to issue 226,000,000 shares of common stock, par value $0.00000002 per share, and 100,000 shares of preferred stock, par
value $0.01 per share. As of May&nbsp;1, 2020, we had 105,998,677 shares of common stock outstanding and no shares of preferred stock outstanding. Also as of May&nbsp;1, 2020, we had outstanding (i) 11,159,988 shares of our common stock subject to
outstanding options, with exercise prices ranging from $1.21 to $6.47 per share, (ii) 16,061,602 shares of our common stock subject to outstanding warrants, with an exercise price of $2.54 per share, and (iii) 6,637,150 shares of our common stock
available for awards under our Amended and Restated 2008 Stock Omnibus Equity Compensation Plan. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc236540_9"></A>LEGAL
MATTERS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The validity of the securities described herein will be passed upon for us by Morgan, Lewis&nbsp;&amp; Bockius LLP, New York,
New York. Certain partners of Morgan, Lewis&nbsp;&amp; Bockius LLP own a number of shares of our common stock which represent less than 0.1% of the total outstanding common stock. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc236540_10"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The financial statements as of June&nbsp;30, 2019 and 2018, and for each of the three years in the period ended June&nbsp;30, 2019, and
management&#146;s assessment of the effectiveness of internal control over financial reporting as of June&nbsp;30, 2019, incorporated by reference in this Prospectus, have been so incorporated in reliance on the reports of BDO USA, LLP, an
independent registered public accounting firm, incorporated herein by reference, given on the authority of said firm as experts in auditing and accounting. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc236540_11"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC allows us to &#147;incorporate by reference&#148; into this prospectus and any accompanying prospectus supplement the information we
have filed with the SEC. The information we incorporate by reference into this prospectus is an important part of this prospectus. Any statement in a document we incorporate by reference into </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
this prospectus will be considered to be modified or superseded to the extent a statement contained in this prospectus, any accompanying prospectus supplement or any other subsequently filed
document that is incorporated by reference into this prospectus or any accompanying prospectus supplement modifies or supersedes that statement. The modified or superseded statement will not be considered to be a part of this prospectus or any
accompanying prospectus supplement, as applicable, except as modified or superseded. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We incorporate by reference into this prospectus the
information contained in the documents listed below, which are considered to be a part of this prospectus: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1262104/000119312519232454/d783135d10k.htm">Form
 <FONT STYLE="white-space:nowrap">10-K</FONT></A> for the fiscal year ended June&nbsp;30, 2019, as amended by the <A HREF="http://www.sec.gov/Archives/edgar/data/1262104/000119312519308275/d805454d10ka.htm"><FONT STYLE="white-space:nowrap">Form&nbsp;
10-K/A</FONT></A> filed on December&nbsp;6, 2019; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarters ended <A HREF="http://www.sec.gov/Archives/edgar/data/1262104/000119312519287262/d667344d10q.htm">September&nbsp;30,
 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1262104/000119312520026751/d879582d10q.htm">December&nbsp;31, 2019</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1262104/000119312520135561/d888492d10q.htm">March&nbsp;31,
2020</A>; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1262104/000119312519189160/d769812d8k.htm">July&nbsp;3,
 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1262104/000119312519308280/d842836d8k.htm">December&nbsp;6, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1262104/000119312519316554/d852426d8k.htm">December&nbsp;
18, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1262104/000119312520080639/d898951d8k.htm">March&nbsp;
20, 2020</A>, the Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1262104/000119312520105808/d891047d8k.htm">April&nbsp;14, 2020</A> with respect to Items 1.01,
1.02, and 9.01 and the Current Report on Form 8-K filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1262104/000119312520106585/d898635d8k.htm">April&nbsp;14, 2020</A> with respect to Items 5.02, 8.01 and 9.01; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the description of our common stock contained in the Description of Capital Stock of MEI Pharma, Inc. filed as <A HREF="http://www.sec.gov/Archives/edgar/data/1262104/000119312519308275/d805454dex43.htm">Exhibit
 4.3</A> to Amendment No.&nbsp;1 to our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended June&nbsp;30, 2019 and any further Description of Capital Stock of MEI Pharma, Inc. filed thereafter for the purpose
of updating such description. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also incorporate by reference all documents filed pursuant to Sections 13(a), 13(c),
14 or 15(d) of the Exchange Act after (i)&nbsp;the date of the initial registration statement and prior to the effectiveness of the registration statement and (ii)&nbsp;the date of this prospectus and prior to the termination of the offering of the
securities under this Registration Statement (except in each case for the information contained in such documents that is deemed to be &#147;furnished&#148; and not &#147;filed&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Statements made in this prospectus or any accompanying prospectus supplement or in any document incorporated by reference in this prospectus
or any accompanying prospectus supplement as to the contents of any contract or other document referred to herein or therein are not necessarily complete, and in each instance reference is made to the copy of such contract or other document filed as
an exhibit to the documents incorporated by reference, each such statement being qualified in all material respects by such reference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You may request a copy of these filings, at no cost, by writing or telephoning us at the following address: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">MEI Pharma, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">3611 Valley
Centre Drive, Suite 500 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">San Diego, California 92130 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Tel: (858) <FONT STYLE="white-space:nowrap">792-6300</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Attn: Investor Relations </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Copies
of these filings are also available, without charge, through the &#147;Investors&#148; section of our website (www.meipharma.com) as soon as reasonably practicable after they are filed electronically with the SEC. The information contained on our
website is not a part of this prospectus. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc236540_12"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the
public over the Internet at the SEC&#146;s website at http://www.sec.gov. The SEC&#146;s website contains reports, proxy and information statements and other information regarding issuers, such as us, that file electronically with the SEC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>17,500,000 Shares </B></P>
<P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g236540g63p02.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:32%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center"><B>PROSPECTUS SUPPLEMENT
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:32%">&nbsp;</P></center>
<P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>Jefferies </B></P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>Stifel </B></P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>Wells Fargo Securities </B></P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>LifeSci Capital </B></P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>H.C. Wainwright &amp; Co.
</B></P> <P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">December&nbsp;1, 2021 </P>
<P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g236540g09h85.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g236540g09h85.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[13>4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %,*^4Q0X0DE-! 0      $L< 5H  QLE1QP"   "3E<< E  "')R,CDS
M-S0Y' (% "I-:6-R;W-O9G0@5V]R9" M(#(S-C4T,%]-14E07U!R;R!3=7!P
M+F1O8W@ .$))300E       0\B!2YC?642$P=I:$]CXEZSA"24T$.@
MY0   !     !       +<')I;G1/=71P=70    %     %!S=%-B;V]L 0
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M;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP
M $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/
M8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M1W)N(&1O=6) ;^            !";" @9&]U8D!OX            $)R9%15
M;G1&(U)L=                $)L9"!5;G1&(U)L=                %)S
M;'15;G1&(U!X;$!RP           "G9E8W1O<D1A=&%B;V]L 0    !09U!S
M96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M    5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D
M       08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M
M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12
M:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M
M   0 [_^-0 "  (#O_XU  (  CA"24T$)@      #@             _@
M.$))300-       $    >#A"24T$&0      !    !XX0DE- _,       D
M          $ .$))32<0       *  $          CA"24T#]0      2  O
M9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:
M!@       0 U     0 M    !@       3A"24T#^       <   ________
M_____________________P/H     /____________________________\#
MZ     #_____________________________ ^@     ________________
M_____________P/H   X0DE-! @      !     !   "0    D      .$))
M300>       $     #A"24T$&@     #-0    8              P4   =?
M          $                          0             '7P   P4
M                     0                         0     0
M &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   P4
M    4F=H=&QO;F<   =?    !G-L:6-E<U9L3',    !3V)J8P    $
M  5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N
M97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
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M=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*
M    #     (_\        #A"24T$$0       0$ .$))3004       $
M!3A"24T$#      *5P    $   "@    0@   >   'O    *.P 8  '_V/_M
M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+
M"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,
M# P,# P,# P,# P,# P,# P,# P,# P,# P,_\  $0@ 0@"@ P$B  (1 0,1
M ?_=  0 "O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04!
M 0$! 0$          0 " P0%!@<("0H+$  !! $# @0"!0<&" 4###,!  (1
M P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R
M@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&
MEJ:VQM;F]C='5V=WAY>GM\?7Y_<1  (" 0($! ,$!08'!P8%-0$  A$#(3$2
M!$%187$B$P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MQX?>FHS<[B/JJJ?NSW+.7MH1M8J>ZF"2?7FFN-QX?>FHSXWRA]5.S/<L[O\
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M1;KSL+8J^Y6NW:[RX5NKMS4Y]MO!5X;F>W65THA=.5+;XR,+;KM?*PNF@QR
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MX< FN=P\>:=A]Y)WAVZ_I?5?9C2PW#@$USN'CS3L/O).\.W7]+ZK[,:6&X<
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MN_/W?8UPU?/8/[.!]*_\/)T_Q/WO[J>WK?QX?<R9Q_[WN^S6IY[.=OR<MO\
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M1[Y@&LXCW^[9GDV;8SD6Y4@(MRP&;!*([#;P\9L^"5%[309B9<,NBYRX8:B
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MEU]?TTD)[CZXW<9A=.EG:L>+40ARX^.Y@_LJ=^7M[%96;8G6SV ; 3<Y$VL
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M0G3D>+3/*5WK^B7&\<0G3D>+3/*5WK^B7&\<0HA4Y'/"XUY:?PQO#B\!>*]
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MHB:(FB)HB:(JM[J?G3_'5;M'>/6H[8>X^I8B:1L(5U,Y0T;$ADCEL)4@ 1K
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MU>'U.X]Q:)E@L6(&OQG)SA=NB9:#&7NL&64%G'.1=5S02VH4MGFX $"UAO(
M-^R^?5<%:QG_ "J\FK0;!<2Q?%&% F93$^2VRHBP("BJ,3W8-K:[(ZP2F"]B
M^7G7^W]<^#&BCK%IE782CLLH#5608@&\@9=0OF/&QO;KV+9C.5);A7DV.NVO
M'EL0X[D(]4W&I18DOZ?*,HQ9T54!8U(>37F+3FXS(UV5UV//ZD*,C#*IV=1V
M) A+'(ZV6^UK9 W-]F=QLM8$V'5B+#EAP V>45"8CC#B<9N2*M\I>YC*T8U
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M?$$9&X.U2!>3)OL+;Y#=]>=L2S,JC)AO8[&66P!/C+M1+J9'@%8I()'_ !F
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M31%5O=3\Z?XZK=H[QZU';#W'U+7+=:]*/*%M@8;.J0*U6RK2(8B(+"O2K13
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M$ZG$OP-<;Q:OK<3K_*123UN(5=16U4SM'9=:6HJI7332'_GFPUY'N=86 O8
M#)0Q7))>;DW_ ##S6/\ :)V/Y3*[T9G^O-<+S)<0_:'1?1V7[94Z$?"/R#S3
MVB=C^4RN]&9_KS3S)<0_:'1?1V7[93H1\(_(/-68.0S8S)*OW2:]G1S21<%Q
MJ=5=T:HG.[5YVD=QXHG;X?C7CVD>9+B!_P#S#HOHY,/7C*=!;:[@PG+B<]ZO
M>T3L?RF5WHS/]>:>9+B'[0Z+Z.R_;*="/A'Y!YI[1.Q_*97>C,_UYIYDN(?M
M#HOH[+]LIT(^$?D'FGM$['\IE=Z,S_7FGF2XA^T.B^CLOVRG0CX1^0>:>T3L
M?RF5WHS/]>:>9+B'[0Z+Z.R_;*="/A'Y!YI[1.Q3M_=,KNUV_P#9F=?_ />I
M_BGY]4?@2XB"#^4.BR__ $[+Z?\ ]M)T(^$?D'FO<^ XP["\*QG$Y#H["3'J
M@6K><R+J9A3AF\U9FCNFF="CU[:1K+(K??NU^T]!=&GZ'Z'Z.:+25;*]^ X5
M2X:^M9%[G94FG9J&9L+IIC$'[=0RO+<@7$WMO #0!F<AU'J &[+9L6W=KWS?
MA-^77K+'LXCFK<=O \D[7OF_";\NECV<1S2X[>!Y)VO?-^$WY=+'LXCFEQV\
M#R3M>^;\)ORZ6/9Q'-+CMX'DG:]\WX3?ETL>SB.:7';P/)0RU1) >VWMF-_W
MD7_].1W>"]K_ .^EN[B.:7[^!Y*9VO?-^$WY=+'LXCFEQV\#R3M>^;\)ORZ6
M/9Q'-+CMX'DG:]\WX3?ETL>SB.:7';P/).U[YOPF_+I8]G$<TN.W@>2=KWS?
MA-^72Q[.(YI<=O \D[7OF_";\NECV<1S2X[>!Y)VO?-^$WY=+'LXCFEQV\#R
M3M>^;\)ORZ6/9Q'-+CMX'DG:]\WX3?ETL>SB.:7';P/).U[YOPF_+I8]G$<T
MN.W@>2=KWS?A-^72Q[.(YI<=O \D[7OF_";\NECV<1S2X[>!Y+HF)_@6/],L
M_P!HE:':>\^M&[!W#U+2[C\-W'Z9#^RZ[3J'>?4U.L]P];EC]15-$31$T1-$
M31$T1-$31$T1-$31%5O=3\Z?XZK=H[QZU';#W'U+%1!!SRFR3"#32*4J*^6"
M*1ZHD$"(BN>Q55$3M(G'M?BU$&STN]95_K;7> !>:P?1Z*IUMKO  O-8/H]$
M3K;7> !>:P?1Z(G6VN\ "\U@^CT1.MM=X %YK!]'HB=;:[P +S6#Z/1$ZVUW
M@ 7FL'T>B)UMKO  O-8/H]$3K;7> !>:P?1Z(G6VN\ "\U@^CT11IJVNZH"3
MJ -$66?CP&A1%1 R'(BIS."HCFHO;_'JC/Q/ 7'J4.7@.)L?6N.9WO-M_MZ7
MG0%Y0V$I6#8;59M/$#6U4BWM=9GDUT@=%TY@_36%41$(^U88@8XPUH 0PB9B
ME=316QRV6V;#[>CT]AOVV]^RE&\N.TM)!W!V)E8Y8\$R\R,N6N'OBK0ZJD#Q
MDB.[HJ>#%\A==9)3O/QZG6I+9:6@DC&L=<L]O9EU]N?MM[$LX[+6[\[7MQN1
MU#TC,8',>41L]AXA)#QKB[D%*NQ7P4V$73V2I0X[F.0G6 )YU6%6VU$C<&O:
MI,AIS+"EBN(F"DG0,:3,.R[?8<[>C@EB3L%M]^WD+VX99K)S[_[""FP5A61B
M"VA%8=:QU1.(Y*/;,BK#[*K/!(JIL>8>)?C'4UO%)BY0\.2='6F$,JG#023-
M"W7?VM]Y[>Q"'=0&W?EUG;LOLRSSWJ\3OML@&3:AD6<\9M(?#76H/W/\T><%
M+*%>V+B9 H\5<4^K%"QC(2+&ZBB?3U;*6S2R/%<)*C67;[=G7EVA+.(OD!VG
MN'HV[;;+&RZ+0WV%Y/,:/0O L):Z-DAS&UDL'4R/M;RD2.5Q(<+4(99XW<C3
M"HY28.I&S311CEA3$Q._L\1?=[=^2V7K;7> !>:P?1Z(G6VN\ "\U@^CT1.M
MM=X %YK!]'HB=;:[P +S6#Z/1$ZVUW@ 7FL'T>B+D6^]L3A>U>49/CT( =Q4
MI4RA$OK@261OFNJX63G0$CRP2M="1(U6RQO;Q5'(B.:BI\Q\LVDN+Z'^3/2O
M27 :AE)B^%4M#+15#X(*ID;Y\6P^DD+H*F.:"0.@J)6V?&[5+@YMG $82$M8
M2#8BULK[2!=?.#VTF\/CBD]$<6^J-?SN\ZCRT_K)1?1[1_[-7&Z63X7@WDGM
MI-X?'%)Z(XM]4:>=1Y:?UDHOH]H_]FITLGPO!O)/;2;P^.*3T1Q;ZHT\ZCRT
M_K)1?1[1_P"S4Z63X7@WDGMI-X?'%)Z(XM]4:>=1Y:?UDHOH]H_]FITLGPO!
MO)/;2;P^.*3T1Q;ZHT\ZCRT_K)1?1[1_[-3I9/A>#>2>VDWA\<4GHCBWU1IY
MU'EI_62B^CVC_P!FITLGPO!O)/;2;P^.*3T1Q;ZHT\ZCRT_K)1?1[1_[-3I9
M/A>#>2>VDWA\<4GHCBWU1IYU'EI_62B^CVC_ -FITLGPO!O)/;2;P^.*3T1Q
M;ZHT\ZCRT_K)1?1[1_[-3I9/A>#>2>VDWA\<4GHCBWU1IYU'EI_62B^CVC_V
M:G2R?"\&\D]M)O#XXI/1'%OJC3SJ/+3^LE%]'M'_ +-3I9/A>#>2>VDWA\<4
MGHCBWU1IYU'EI_62B^CVC_V:G2R?"\&\E]'=AK<G-=K,9R?(H0#+FUZ[2&DL
MK@162N@N; 2+FCC#Q01(P<>)G-CC:BJU7JBN<Y5_H?Y&-)<8TP\F6BNDF/U+
M:S%\4I\0DK:AE/3TK)'4^,XC1Q%L%+'%!&&P4\32&1MUBTN-W.)/*82YH)VD
M+K_6VN\ "\U@^CU]062=;:[P +S6#Z/1$ZVUW@ 7FL'T>B)UMKO  O-8/H]$
M3K;7> !>:P?1Z(G6VN\ "\U@^CT1.MM=X %YK!]'HB=;:[P +S6#Z/1$ZVUW
M@ 7FL'T>B)UMKO  O-8/H]$3K;7> !>:P?1Z(HA5=7H\-$ #3B8U%X"P)Q3H
M"%X*G,[:<41>W^-$T12^MM=X %YK!]'HB=;:[P +S6#Z/1$ZVUW@ 7FL'T>B
M)UMKO  O-8/H]$3K;7> !>:P?1Z(G6VN\ "\U@^CT1.MM=X %YK!]'HB=;:[
MP +S6#Z/1$ZVUW@ 7FL'T>B)UMKO  O-8/H]$3K;7> !>:P?1Z(G6VN\ "\U
M@^CT1=.Q"..*CACB8R.-I=FC61M:QC4ZXE=IK6HC43^Q$35.T]Y]:@V#N"TZ
MX_#=Q^F0_LNNTZAWGU-3K/</6Y8_4531$T1-$31$T1-$31$T1-$31$T15;W4
M_.G^.JW:.\>M1VP]Q]2Q$QD=<%=6$K'R1 (8;)'&K4D?&*%'.]C%<J-1[FQJ
MUO.5$YRIQ[6M%3.VFIZBI>"YM/!-.YK;:SFPQND+6ZQ#=9P:0VY N1<@9J$Z
MK7.VZNL;=@))7$<(Y1V&9=C&5Y6:*5C==B%.+?V+2[&BM7D5A=387,: K2V9
MJ3640E6;U35O;$7"]D;>8_I%YG@L$\H^#XKAF+8I4Q287!A%'%7SB6HHZMTM
M+-25-8WH/<<\I?4-AI9NEI2&R,<&C/6.KPH:^*6.635+!"T/==\;[@L,F1C<
M\:P:TDM)!'7;.VU_=>I*@>NDW J;?;@JZM$KJ8&_=66K[&-\8+TLD)Q(_(!
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M$Z!DL5,Z62)U7")6,ULM;:^F<PO+]758U[@6N.J']'9H(:0]PZ6,$,UB"X7
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M^IP3_C1.A'Z0<!]9/:S[9_UF, \G0_;G3S<_)O\ [QF@_P#4X)_QHG0C](.
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M;3AU'43.I:GW5!)4XIBM5.Q^I!'T)J*BMDF?2%E-3M=0O>ZC<(8RZ D74%'
M=4&-SBQX>USI)7N!RRUGR.>8P&M'1EQ9EDW);#4D\FRGQ"^QZJO,;]B*&XAD
M%U!#?VMB,\Z,##UQ.1AO5A)!$[Z^GP^1E<$1+)-!(#,:(]MH]Y?(IM$L I,-
MJ,(IZ'4P^KJ:2MGIS4U;P^IH8\/CI9.DDF?*WHF870MU&O;&_H+O:XR2E^3*
M:%D?1-C(871NU=9QNZ(1AAN7$BPBCV$7+;F[G$NTAM'R4*JT K:L4<F2BKJ:
M^85C^27T]4* %9;;4%80:6/?L$L81Y8,,/EZ5#AVP4YMB4Y3&%(5UD/DZT.@
M-,8L),7N1]/) V*OQ*-H=2MP]L'2,;5ALP9^*Z!^K,'M=)3B5X=*][WZ_<-,
M-4LBL6$6L^0?FB(-!L\ @"GCM<&Y;=V9<3A+^EY-U81665-D-D0-0-Q>"?;_
M !*Q(,-R)U[="56+]71VAL!,T4-AF]=+TIMC!'3AW8AC"*N&[6:SXDGDVT>-
M502P>ZZ2CHFQB3#X*F;H:PPFH-.:F621TSVPNJ97,#GET9<XT[H3)-TN/XO@
M+HRW78Q@L8P]W1O UR-<;?>Z[M7;:Y#=76<5O#0.2T=8!7\=K2N,Z +*02X,
MGR6"(Z %F+UM81%#%91BV_.9C>+NK:U(BY+!C0[ $,EEHI)?9.T#T6=41U9P
MUXGBF@G:]M?B+ Z6GCPZ&$R,95M9*V./": -9(US-: /U==[W.V>XZ?6#NC(
M<'!P(?(,V]'JW ?:W\DRPMJW!-@7&]ZA,Y-3;AKJBS&J[*EO*"G$.9D&35T5
MF],+VP)J61&QV<<-SBTE W;48OJU\U 1;Q5D=BR2S,CD,Y$&AVCU-/!4T]%)
M!/3FGZ.2&NKXG%E-2X91Q03%E4WW12]!@^&B2EJ.DIIGTD<TT3Y2][LA2P,+
M7-C<TMU2TLDD:;,;&P--GC6;JQ1W:ZX)C:2"=N6PS"N3P>/(/@[@I(LDIQL?
M8E1DV3026-37UM=+#,"YEI%+S)ZO':WIKT)6.MA:^.(D\QCY&2Z*;071BC94
M1TN'R4[:JDBH9A#7XC&74\+*6-@:65;3'(Z.BI8YIF:LL\<+63/D:7!V#:.F
M9K!L9;K,;&2U\@NT:K0 0_(V8P$BSG- #B1<+O&/T-3BU)58Y0AMKZ:E"@KJ
MT)DDTR#"#,2.&+IB9)B)5:U$YTDTLDKW<7O>Y[G.7T=!04F%T5+AU#$(*.BA
M93TT(?(_HXHQ9K=>5SY'G>Y[W.<;N<222>0QC8VM8P6:T!K1<FP&0%R23WDD
M]JR^N6LU&E_G(/\ >D?Y(K5&WT.]14.STM]87FW<'#-TCMSPLLQVRL68N#8;
M?#$U@-UE8I[P(3+B:_*JJT;/:K!BQ9)YZD')Q,APRRL9<=GLSJ6QDMJZH T[
MK]5M]^NWI].85N+6(&T[LA?*YV[ <CEW%<^IC>4[C]4?725N8VQEBD1@UA/'
M@%MUA*2E))/ KWV%D'*77]4ST8-3#9//F6U'N6FV,(3'&:=7I/\ !7WAZSV@
M[K\-]R=O:%+'N>5H;<T5>=4%TT!4%#7Y+;5X> ETU:45:TTV47-! 8PNS6*K
M8[(ZS''6A5DTZ@$K;"WQ^*YF8?9Q0:HSOENN3D#;:<MFX[2+KKVUNW-C4D,W
M!R>6=-P<AQ\2#)AY8PXHI+AD43")9G5[G#I$^0=DL0@:1#CK.^%[R10*$>F*
M&UB0+C.U]W>>ST6V9+D P^_EQC]0;#;9I!#%:X#(Z,!<:&NHJT*LVLN,\FD2
MT@EG,LS<HGW)I#*RWZH$@#JXZJJK0Q7QR'/X(=6^P'/8<]YS\?&RL&7O*NM*
MZ2!F-6@"/HKX"T8X7"H#)+>':G'$IS*4ROOEF'@L]VUR<<F='K,/0L')#;5Q
MH$4I7WN>9OZ-^SNL1;M/:L_8D\J"NC.L GEW;Y(SE@HEKL$":(IL&ZK($#.0
M12'/I.L&UL]>XU;)Q!647:V UU!*'7X\\?;[E+MRM?K-]@ZB3VBY/AN6JUI_
M*.8+<6660YI7PE8[DC+)O18>HPHU/5[A08];U/L?+=:0Y^?:#;<NBJZ*N%Q^
MSAM+>0FI4E&C4I9'5V"]\^OJ+A;:;VMMX9KVX(I*B"N-;&PQPT#BV1+QB84L
M35(;&J*O%C9N>C%XKQ:B*G:7112-$31%P'E0_P#09G7]S2_^8ZC7Q/\ ",_U
M*Z>?]APS_P!?PE:Y?^C=Z/6%\;=?R$L=QX%<--+'<>!1-+'<>!1-+'<>!1-+
M'<>!1-+'<>!1-+'<>!1-+'<>!1-+'<>!1-+'<>!1-+'<>!1-+'<>!1?8_DM_
M]!F$?_1=_P#F*VU_7K\'+_4KH+_V3%O_ *BQA<V/\QO<O0.OMJS31$T1-$31
M$T1-$31$T1-$31%#+_EA?IC?\N1HBF:(FB)HB:(FB)HB:(FB)HB:(FB)HBZ)
MB?X%C_3+/]HE:KMI[SZU&[!W#U+2[C\-W'Z9#^RZ[3J'>?4U.L]P];EC]15-
M$31$T1-$31$T1-$31$T1-$31%5O=3\Z?XZK=H[QZU';#W'U+$R!P6(MQ7E(]
M1C^JPB$C=S'K 4%'!*C']M6.6.1R-<G;:O!4[::B@V9;S_\ ,=RX[><F_:J^
MA:--3S!"M*K+!0JYX< 3K*NH2L6FM.HY0IQ8[6WQPB"IM+6"&&Q='54IH!(-
MK4AV$19W/??+/T>JV75OZK:\1R6,!ALUO,?MLGQ^\0NBGALX# S9PQZC)L+R
M0@<-Q(?5#4,DP>I@'@-).J*N5YA@U/(ME;P63V]OXH'. (-C<[;6ZB/5U;.S
M+.:7R6=IC%E=*#9N>X"E"@DEFKBY()*+K=U)8DN/K"TR"P?ULA:^3*VWXX\9
M5I'7C!16UDPME[;^O^*EW&U[9&^5^&W+8-G;WK-0<GK;T8B!\3LD2O"K+NIK
M:-][-+35HF1@H)=J*-)$LSISR6MN))BB271W2-/@2)S6QZ("X=8SSV&]Q<C:
M3U^I3AMA]NQ,GMLL'!-AM+DK'3S5C(@8QYV-6>(VH1/2H*ALB3E8/C?5(I!D
MP,;13'5XH,]M;3FT6Z[^CQ0EU@!;*^V^PW[;=9ZO2L!+R:-MGVE1<129(-84
M%1C]12$P68RSU:8O7TX%$:*5.!,8V:O7'Z>QB >2_'UMQ)K)](\FUNG63+MZ
M_NW>E YPO8-S]B-FSL'%9:?83"B32CB+#+9Y;/J>.^4C()279&&RHPZF.K[R
M<B"4PL2Y'P+%IK56%0%S3@$-'*%$M;84Y['M]629VMP[-O?GF>]9?%]IJ7%,
MKKLC!)>X?']MJ7;+&ZYT,R3!4M68\V<FS/D/FAM327L"A$EBK*QX \1L<DAW
M7#B+%,\MFW/[MO7GO[=W5=%4T11I?YR#_>D?Y(K5&WT.]14.STM]87)\EWPP
MO$LXCP2Z8>,<X2K,FM.K<4;7C16\=Q(*KJJ?)X,T-CB92&RV!U1B5C5UD"(2
M><,+";,)%0"1?:;D6L;[]UK;L[VS.]2#M\=L (Z.67)QWQ9 >57@O9"1$YD@
M5;%:$3$0%QBE-A2 NKAA;!!.467=5$ 8Q"F-5KV]O;DF?4-GB,KV[KW[@>Q4
M^[GM8V2R@(RP,,RIDDA/ FCGG,AG99U]1&+''7Q&QF6!)UM4QC58,I-H_KF$
MUX4<LCHV$SW'VY=:QN:;TTU- 6%A[0,RRL/K>3/0]<9JF(>H+;!)-;RVDM>2
M&\<1I=>/.V)ZH/86U2$;*(18"13DL=IR&_>=VW?;^%^K;ES9[+:B","$KA[+
M%9<GM5/L)H#Z(>$=TTS2!YJ^(>:,>1B#.1A:&*B&$SA!CURN**#9D" +]5KV
MW#T\UAY-[-N!6S):715(4-25F0%5UO1W@IT%9;,BD#D8QE?- ?(J2N;-%5$'
MN'<,?TW,2O.4=W(#QZ[>V\64F+>;:R=]@R'.*.1:N,Z8QS)9EB9!65]Y:6!$
M$R0=$8.&!C5\000&\B&)M82QTB2HQCRMCN-]W7M]O\UBZ[?S:JPKUL'91%7=
M&0<-.'9"F0V ZUS[-A1,@X\)*.KH^LULJVD,DU:U:RRAD*8576 XI/1N\<U?
MGWPVV&M[^F)O'028R]8;FQF$(AJAB&'&5<P@Y4C&/LBA[0 FM*BJX3E%-8D!
M'1.>U=,K=OA93,VW'Q/?F+9\;6O?.W!OOMD3;5E3%?,YEP\F*NMT:R2HFF'$
MP0Q(""(9Y2:J6=FXN.PPLN1*]6DN)A*4975SK&^BWIY[+=J"^>X $[QPVD]G
MHOG;H]%> Y'5#6]<LR#$/*A=$3%T)0AE>81765>9"CY&Q&5UB(4 7&V21D9(
M\K&22-1'K#V>WB?6@O;/;[;ES_>_(1\4VRR/(2Z.MR0:L6JFEH[B-DU;8))<
M #-C*CDBGC<R-\[9VHZ%Z))$Q>"*B*GS?RNX]3:,>3G2?'JO!<.TBIL.IJ*2
M7!<6C9+A]>)<4H:9K*F.2*9CFQ/F;4,#HW6EB8; BXCR&M)(U@+9>D6ZCL.>
MS@OGU[9G&/ZONU?Q77_4NOP)YQ6C'["/)I\VT7V4M'3#]&.(^JGMF<8_J^[5
M_%=?]2Z><5HQ^PCR:?-M%]E)TP_1CB/JI[9G&/ZONU?Q77_4NGG%:,?L(\FG
MS;1?92=,/T8XCZJ>V9QC^K[M7\5U_P!2Z><5HQ^PCR:?-M%]E)TP_1CB/JI[
M9G&/ZONU?Q77_4NGG%:,?L(\FGS;1?92=,/T8XCZJ>V9QC^K[M7\5U_U+IYQ
M6C'["/)I\VT7V4G3#]&.(^JOH=0X#MO<45+;R;;X)!):U%9920LQ2A<R)YP4
M!3XF.=7HYS6.E5K7*B*J(BJB+K]\8%H)Y.\7P3!\5D\GFA,,F)X708@^%NC6
M#N9$^LI8JAT;7&B!<UAD+6N(!( )%UO ! -AF+[ LK]S#;3\GF#>B5!]7Z[7
M\FGDX_4#0OZ,8-_8U;#<. 3[F&VGY/,&]$J#ZOT_)IY./U T+^C&#?V-+#<.
M 3[F&VGY/,&]$J#ZOT_)IY./U T+^C&#?V-+#<. 3[F&VGY/,&]$J#ZOT_)I
MY./U T+^C&#?V-+#<. 3[F&VGY/,&]$J#ZOT_)IY./U T+^C&#?V-+#<. 6P
MT==7U(3JZJ #K*\4HMHP->+ $&.U\SI7M@%&9'!$U\LCY')&QJ.D>]ZHKG*J
M^JP_#L/PFC@P["J&CPW#Z8/;34-!30T=)3MDD?,]L--3LCAB#Y9))'!C&ATC
MWO(+G$F[-BS&N8B:(FB)HB:(FB)HB:(FB)HB:(H9?\L+],;_ )<C1%,T1-$3
M1$T1-$31$T1-$31$T1-$31%T3$_P+'^F6?[1*U7;3WGUJ-V#N'J6EW'X;N/T
MR']EUVG4.\__ .J=9[AZW*!P7W%_5J)<;QQ]/JS5."]WAVO=TL=MLMZMQLOG
MN31$T15X+[B_^O\ _J?KT14T1-$31$T1-$31$T15;W4_.G^.JW:.\>M1VP]Q
M]2QHY [)362$01O0I55LDT4;D18(."\'O:O;_%VNWJ6O_F!ZT!L/2[J)ZSN4
MKJH3PL3SH?Z35L>SB.:7';P/).JA/"Q/.A_I-+'LXCFEQV\#R3JH3PL3SH?Z
M32Q[.(YI<=O \DZJ$\+$\Z'^DTL>SB.:7';P/).JA/"Q/.A_I-+'LXCFEQV\
M#R3JH3PL3SH?Z32Q[.(YI<=O \DZJ$\+$\Z'^DTL>SB.:7';P/).JA/"Q/.A
M_I-+'LXCFEQV\#R3JH3PL3SH?Z32Q[.(YI<=O \DZJ$\+$\Z'^DTL>SB.:7'
M;P/)19C!$)"_A8J_OL_'@3"J(BADM155'JB=M>"<>'%>U^/0"QZMAZQN*$W'
M7M'4=ZYCEVT>"9O>EWM[86#W6 =4(?6#7 0M:6M%(?/4%2+&.EG$0%/82RHP
M>QA$(='$TT4F))(Y+:^=QQ;LZNL9^A XM/8+G)KKW.W>+'_):]?<GG:?)+B2
MZMW61!"NEG$';E,\05582U=+5]=Z>&.9JUMO$F/4UB+8"OC("N:^"U#? 8BR
M++=W%OHZTUN_Y)/>-GM<Y;;RR-AMK2:ZXK9.G=!>6EI<6"S6H1J2GW$=%&=(
M\2QA,K2()$QVL7J(L$@)W,G1X[FSO;I;N^4.:7SOGL 'O3U$G=UW_P U/PC9
MC;?;W)YLMQN0N*UEQU,71Q]^EDUM1S:!JQ2SEODL#ID7&JSHB;,TZ<6)DHH;
MQPWH,U;M'$>GK_S4+B;#JO<BQZLO@[>OOW[5U.QBJK6O/JSIQ)@K((JO,BZK
M@;THAL$@Q,?.25%;SX97MYR*BIQXHJ*FEM]N+>:M]U[]63MO!<+.Y/\ A-Z!
M8!9/E617W7CK#-;-GNJN,,@W'J>.C#(@$<(0^ 5H75D@]1,675UMC8FW56,'
M>.ALX5N[Y0YH'$&XZKV]Z;YWOU'LS[\E^C^3IM-84H-"^:W&$KZ^WJH)PLKF
M$.ZW9 S)X;L60J&1KI&6(N8Y ),KDYS8#&.@6$@4:>)8]GRAS36-R>LF_P":
M<R-E\ME@+BUKYK(P[$;8QPVL$Q-L<RVI[;'GN/RF:>4&AN4NW$5-9(V:)P0H
MQ627IP#F*XD0BP5D<Z""5PH:W=U=;?3U\%+G;UWN+-(V;+Y'J ODKH6QVVP1
M#2E-MC)^J^N,LI^2H6\FT?E=CF9%F0YZH]Y9=U92N(1') HL0XL<,3(EY]MW
M?*:FL<MU_@NZ]N_-68=A]L!B>J!R+4=LEF?9'BPY1)&);I9MPMIU?:PI)P)K
M"5V_QATHB*Q'H*5"YZC6!L,TMW?*;S5OW[!_U7=5^9X]BZ;BU2!C%(/4,M1S
M9&DVMD:;),- XVUO;8Z]N3&CMGD:-&5;61I$(K9)&BQ2,';(]L:.58]G$<TU
MN_Y)ZO0M'WQQXO.-L,DQ2B)K76USUJA#0H^& ?GP7->9(LLR+)T;4A'D5%YB
M\7<$7@B\4^:^6#1;%=-/)OI1HM@HISBF,4U%#2"JFZ"GUX,5H*R3I9FLDZ,=
M#326)8;NU6]=UB\:[2T9$VV@@;0=W8OGG[4+=COV'^DD/J^OY_\ FC>5W]'H
MU\]N_L:T= _>WB>2>U"W8[]A_I)#ZOIYHWE=_1Z-?/;O[&G0/WMXGDGM0MV.
M_8?Z20^KZ>:-Y7?T>C7SV[^QIT#][>)Y)[4+=COV'^DD/J^GFC>5W]'HU\]N
M_L:= _>WB>2>U"W8[]A_I)#ZOIYHWE=_1Z-?/;O[&G0/WMXGDGM0MV._8?Z2
M0^KZ>:+Y7?T>C7ST[^QIT#][>)Y+ZE8U&RKQS'ZPHL%"JVCJ:\E(S('Q]4!
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M/R?/[#<,+<#:G.W/;%]R?,\("O,EVIS4F&Q(&G+BQ_<L;$2KRGINEDLJ*.R
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M*^ZOZUTN=YXE$XK[J_K736.\\47WHPG_ &+Q#_NMCW[(#U_<'0O_ -SM%/\
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M7L"1K/!V',:H8X7+B-9PUR06C0)5W*EH<1R,8_-3YI,!KY\HIPW-11<M&S_
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M6.1\3)")N;T<#'RQL=*YK72,15<FF>7H()IA')+T,3Y>BB:'2R=&TN+(FES
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MQEV4]B@L#U\-O8<^:U:VY,.Z,F&Q8_!=8SDMQ*11GMNLIL7<:'J7&,EQ1^-
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MU6,:U7*Y6HB*Y41%=P3AQ5&HB(J]U>"<.*]K@G:T6*\T\L'_ -W?<+^YHO\
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M/T,/3(U).BCYW,3].Q.D?'&Z:,0RN8UTL37](V*0M!?&V34CZ1K'7:)-1FN
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M1,0,ZU(65L;X3?;_ )W%NOLRW=6]"UO5GM&S(C*UAWB^=]RZ>O*"R3KJ2 N
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MJQ\BO!*EYZ%/J@;,H"N<*&YL#2I)/7ZAZAZ=ZD7VQ&U62QMCML8F>UL) KG
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-[Q$YR+P[7#3:KL7_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g236540g12v45.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g236540g12v45.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1W.4&AO=&]S:&]P(#,N,  X0DE-! 0
M    ';*^=@(X0DE-! 0       \< 5H  QLE1QP"   "3E< .$))300E
M   01\QSQ'3+PED4-3..8<@/#SA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!2WTO
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  (#O_XU
M  (  CA"24T$)@      #@             _@   .$))300-       $
M'CA"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          CA"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              5X   '<          $
M                 0             !W    5X
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   5X     4F=H=&QO;F<   '<
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   %>     %)G:'1L;VYG   !W     -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $    !CA"24T$#      32P
M  $   "@    =@   >   -U    3+P 8  '_V/_M  Q!9&]B95]#30 "_^X
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M,O865^X1]'<UK7-5M9K^M.8 ?V?FND@0VII.IB?YQ/\ M=W_ ' R_P#MMO\
MZ41$)#I^*0Z*2SOVN[_N!F?]MM_]**SB91R6.<:+:-KMNVYH:3H';FPYWL]R
M1B1J0IL*OG_T;^W7_P"?&*PJ^?\ T;^W7_X
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M"C5#1%1C@X>4F*:GL[6WQQIDA8BDJ+:XPL8I9FAVAJ*ELM/5XO_$ !P! 0$
M @,! 0             ! @,$!08'"/_$ &(1  $# @,$!@8%!@D'!@P& P$
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M;YF<[<,C[4=]T^&OC125!?#%8:W,<R6X^\=<=(2,=%]IM@R$K (RD%0SG"B
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MB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HBM*_/J+NG]HJE^]G-$6NW
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M;KB6UAP(36:<%'H4 IQ(&5 +/0GUGO'355Z2]':H8*_2CHX]C7M?#-L8!KI
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M?D>=E#_4*_TQC^?UVXZY[OY]8(Z^.GY@/1%_Y(4_^MND7_>JGYTNGGZXK?\
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MAPDNW7->0(@6!,"2#IXI$9M,=H4.5W^R#[4?@UCZO$1_'@F]]T6X:*RW[O\
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MVDSZD4AILEMHD>X^ LM %UL>BASF2E2TI!/H*6'],;&X5IV37=]$I-H2[:[
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M1MY.;["</]UC?Q'3\\G3S]:F^?LNO_?3ZMPWW? )^4:^3E^PG#Z=WT6-T_\
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M6=&9#$AII]AYMYAYM+K+S2TN-.M+',AU#B"4*;6DA2%A12L$%)(.B2.(\^?
M\"N;NX:@KRHO#@I)YDJX6>(HI6D%2"!?_#MW+&4^/3KD^'<=$!F>PBV8@=ZZ
M4#YNI^__  ]^B#7/,Y_O-O,)HJFB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB^
M/(;G%UP,,("5*"B^5,DJ2G/*V4+)^N)"N4$>)[M:"^N''=HM<T9%SHGKAP(X
MJ[SA !,"=3;J$YG6;=N4&VY6%9I[*.9:UA*G&ED*6HJ4>;F5D*42<$X&<
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M0 =><I; 4^ 24X6M3JCRG)/-XJ!Z:>>Q2+S;(Z1?CV\@>9,!?33'CH81%$1
MC)CD".(Z P&$@!$4M%11SI'*.4I*5<A/H]VBM^>IT[NL>/%>6-0:*PXW*:I-
M/:DI!*7A"C(?1S$JY>=#22DIYBD8[L8R>\D$_OZ^7+]^J]<BGPI:4MS(S,P#
MGY#*89D=D%<O,$=JVH("N5/0#KCKG T2,KW&1/G77YW4(]-@PU<T*)$ADIY'
M#&C-,J6CH>4EI* /22D]4J[B,9(()&67.USIGYX6"\+U$I<F6[(?I5.>><&'
MWWZ;'<5(;*<);[994HD)*4J4I)!P< =VKWY6O^&7+Q4B9XWN1H>HB^DV/)>]
MF$PQ'$1EAAF,"I*&&V$H:0RK!6UR \N5*YCS<N,* *#@YGDJQEI\-./,QF -
M%X6;?H\=3;L>E4YE;9)2L0(R76T$=$MJ;;048(&!Z7Q^(*7BT"#J2;>?.B]<
MNGQ9S*6Y41F8A*@XVB6AIP-J"L>@E;3B483G'HG(]'IG(>>]6.V./$'J\=><
MRH1Z7 B!7FL"'&*RD*[!AEHJ0 ,@EIMOQSW\WK\0 2+6N9F#KRGEIED%3?HM
M,DK4])I\*4\H8S)BQGNAZ%/.MDKY<>'-HI'&3F+P?AU9S"]+$"''BIA,166(
MB4]D(S;3:64MI3RI0E"0$AM( 2GT3T &._3GK\E>7$WM.<D^<EX!;]&2M*TT
MJ 'FSVB'3"BDA065)(<2TA86.G*<Y2,9YB#DI&>O7<"_G707%EZY=-A5!(3-
MC-3&TX*8\IMMU@+3]*L(<0O"DY(2KP]6BL3F+#2T:08'G2+JFS3(<0OJA4Z%
M%6H-@&.RQ'"P% D$M,)4!T!.2O)P,#12\FT6&MNKWB>V,E&11Z;->2_+@1'W
M G"@]&CO)5E)20I3C)6KESZ)!3W X\-%;YY<I$#POEXF%6C0(<%D1(D9J/%(
M6$QV6FT1VPHJ6L!M"4@=HI:B>AYB3W:(;SU<H\^"\3=OTE"D.IIM-0\G!*DP
M(O0C.>4]ESCJ<Y*R>GCHD&,QW6[@1[XY+V2X42<T(TJ$Q)CAQ*E,R6FULDMG
MM&U!M:%I4$NH;4D>A@@*SZ/*21:T:Y\Y^*HQJ/3XCG;1H4:*M718C1X[(4".
M4@J:90M0QUQS#/=G1(N<\K\#SB_5?2V22*13Y12Y)IT&4Z$%/._'8<4/%("G
M6G5 #)[CTR3A6>A(R[LXMW=7#KXU6(,:(PW'CQD1F$G_ #/%0VEI2E@\_.A+
M:$$9[SRCF.#C0F;E(@ "W5'#GG[_ !7C<MVB+<#BJ33^U[4.J=1!BA2EI6%-
MJ4I32E%3:@E0(4"%)"AZM!9([B;QSM?XY1QM?V2H3,ME+,F+&F-())8D1T*:
M<<2!V2@%]HE"49()*',^ &-%(R$ ^8''J/+E9>1JB4YA:Y$:EP8<U2.4OQ(T
M>.X&\@AH/H:R<="5=G@X^E&BL=\9\>1,?CP7H<I,"5A<^#"EO<H27)$5A]8
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M9P@>U1R,#U]1HB\/GK*NU:8F1GWXRD,/@.-N+8=5D_S6ED@1U*"' @.!M)6
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MB\/>Z&X4:QK^W+&V]^V3>]5B7)3I4=^$*E3GJ6ZS"I+L.0%1YK:UK$I"D+0
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M/Y)?=G[OYU8_>_R$4/A%\NYU_.X\!O\ XRV['3_ZJ^B*)W%\NW^QQX#<]?\
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MV=;IG"[ORBCMRKF8N)-5[:_M@S+$=QFCTDMHC=E'*@MO([5(&<G$U/9\;^>
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M4^G*I\J71&V+SMU%M5B?'>E)?J+@K2F'I#J>PD)<*@&GGP5ZAU3[C\;*>_\
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MHFB)HB:(FB)HB\52@PZG ET^H0(U3@S&'(\JGS&&),68RXDI6Q(CR4JCO-.
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M7*I*DE02KF"<)YI%Y\^?F55V=U4%_'P,)HB:(ODU%WLW&<)<4I25 %*<I'I
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M5MM(;D.-$J25<SSW^?@G8//9Q^?)9EF[16G<%*BQ[WHENWQ6F:5[DRJ_7:#
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M(2XDD+0H\IPM)P"@D*!Z$:Q]1AOYL_UG_MK'_.OYYO\ 4;^PIC&GC&938!)
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MI)M&0S)N(&=YM'.\\I6E5+\D3M9:UM[HVAM_O3OUM_ W6W%JNY]=<MJ[I4&
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MZV23,C7/CX^_YJQV>'#A?EI[E42PE)P>538RH-J0@A+JEEQ3H41S!2E$G&<
M]1@Z)'&_7!^"JE((('0YR"1S<IZ8*0>@QC(]N3XZ*JBE@)+@2KD;44J2TVE+
M0;6.;G5S-A*EEPE)4%DCT1CO.B@ 'F/<I^Q'(I.<%60I02$DA1RH   #FZY(
MP2259YNNBJ\SK2&U-Y',E1+81GE0EM20"E2$^BYU*E@N!1"E''AK55JN8ZF
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M\VU"RSQ WW?UM7ILVU:M4I]*H=7W :I5TID-.J=E17Z+5I"&&0A]M)*Y;+!
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M:C\'@'51ZMK7;U2C2#W%I98R27-BQD  K7AW4V8G&@4VN.]B=QIES06[Y:V
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M93'87 7,7#:S+:2XXXQ':>=22AUQ39*3\YQA>_IC7IM<_=C"EP@EO^B4;"!
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MY'$M +@V3(DR2;SQUM&78L!\";?9\)>PZ>7 ^#.S\*YTKYOYQPCGT"0#UZC
MUV%1E.F]PID$;QDM<7#.PN3<=?-<6AO0^;R\D<+Z=@A;:K2I7TJRGO[AGU8\
M?#^'6N(F+$^^_7QT6]4EL%Q)0XYSH(ZI*<9QU!R%>"@#\FL',WVEI( ( ,3H
M0>(&8X9=R<->//Y*@F(\' HR,M@8#?9C '@ >;P^+1]/?9N=6?+Q6WUC V&T
M@#][>,\\Q\5Z5LI6CLU84GE*2%#((/?GJ._Q]G30TF.I&B\;S'-+"#D0;7[.
M8XRM0+@_?#H(,BV1Y'W+X=/MZ-2PI$#LHS"W''E,-LX1VKRU..N#T^BUN**R
M>HYB3CKTZS9VQ<!LW#FEAZ%-E4^L)KL#P27DD>PY[A[,C(B8T6ZKB*]>L:M>
MJZJTL#13, -C=$@@3>#-A<YV"^-6-O+<KLYBIU.G09LYE22IZ5%2]VJ6P$MM
MJ',DA*$I &% ]._71;2Z!=&]L5VXS:>S<-C,<][3C,75;5]9C*;&-HLIO#*S
M6MW*#&46N:)W6@F2N=AMM;5PE)V'PN.Q%##/G>H4W ,]K[6;21O&YB+DDS)7
MEJVUMFUI^.]/H=-DF.T&$!^,7.5@+*RTA1="D()).$JZ'&,8.>NQWHG]'FUJ
M-7#;7Z*[-VCA74_4TL/6.*:RC3(.^&FGB&N._()DVW1Q5I[>VYAF;F#VIB<,
MQSS4JL86EM9\ 2\$7$""#((,0IY^V5HU-F-#G42ER*= 1V=.B*B$"&WR\G9M
M+#N0V4!*%)"1E P3XZW;2]%OH_VMLK9^Q-H=%]GXK9>RL/3PNS\%4=B11PM"
MDQE.E3IAF(8_=8RFQHWWN,-%Y6>$VYC\#4J5\+6J4<36.]7K,<T&J2=XES?5
MP"7>U(,3HOHLV31&*<Q2&X,%-+BEDQH(BGS=D,/I?;#:2Z5#LG$AQGTOH;R4
M+/.E)0>SP70S8F%P%'93\'AZVRL+0P^%PF #*E.EA\/A QN%HM=ZYSW,H-I4
MPT.)<X-]IRX[]IXOUE6O2K5*>)K.J.J5]^7.]=O>N) :T;]0/>"X"!O&&S=7
M*B,W%;"8[?*AEO#;;?0]Q]%(ZXR>H]I(QC7IA2+&MITW!E-C6L8P"S6-&ZUH
M)))#6@ 3-AFN"Y[G%Q<2XDR2;DG,Y7DZ^%USVX@MF.(5WBFVKXCMDZ/9-W)L
MO:C<O;2I6K>-<DVRVY[_ "X=M:ZBKL5:.S.*':<;",40E07!*34E/=NP8G(]
MV-"O1ITW4ZM!U0NB7LJACM9'M4Z@(OPF0#(7%=2<YY>VI'^[,$:?:&ATX7E>
MJMW+QXR67)]3X>MBI2*85U%A WCJ:%-JC17<GF]ZR@5\V5)5A*0G*"@D\XZ7
M:&R]G8^M1JOPW\5595_2/-1[BW@YHI!IX$L=$"Q79X?%?1VEH8XDL+-YKPVQ
M,DPYE3/+/4K$VU^XO&!O'0J'NW2>&/9!IR5/KK,=QW?&JNGSJU[FJ]L/CF;M
M)F-S+E4-;O,N(M;06&R5E'.KI\5T6P&(VDW:+&TZ9;7H5MQU-]1Y- 4P 7BL
MQI)%.SC2]D&(,2=QV@[<W(?N06QOMG==,W]7,^T0!D>$K.#=Y>4##82=@]BT
MD C"=XJD0 ? 9M<GN..I/49[NFO0XFB*U-C*3C2+00YSHJ;P@ 0V&;N1F[ID
M01$GB.JAQG=(/$NGOAH'< .2KIOGR@J0E/P [$JPD D[PU('/M_H7\/9K.FT
MLIL82'%K6M+@(D@1,:3G$GK.:U$R2>)E3&^O*"=/S =B3WY_-AJ0\.@^I?N\
M/F]NLU%'W]>4#^P!L3_CAJ7_ "7T10]_/E!/L [$GJ?Z\%2&/5_4OUZ_?T1/
M?UY03 _, V))Z9_-AJ7RGZE]$4BKY\H*KE_,!V*3@YP-X:B0<=0#_0MXGIT(
M\?7I:"+R00"#$'CD9CA;K60+1,MF1:\0>.1E4O?CY0)2BM6PNQV<]PWBJ&,=
M_0>]0X/QYZ#N\=*<M=+SOMB( #3_ %O:ZLM28.2XU2G4>06U T"+%DY'DX3X
M77BJ%R\?M38>C3-@=BWF'TLA;9WAJ _0E-J623:J@>TY#@8]$D'KC!U8S"8#
M&,W*V%+P<Q4J;PL9 ]EE,P#$7O%Y7883$##/:\L-1S)@A^YFTM),L?QGKYW6
M);7X@.-:^=P-Q=IXO#?LHU+V>KMKPJO(?WGG.LNJEV[;%X4A4- L]HH<CLUN
M A2"ISF4TI:2CG"4Z\1A,/6ITJ3*;:;*3:;&@R\ 4X@""P@ " )/,DR5KI5G
MLJUJCYJ"JZJ=T'<(%3>MO0X$M!L8 )T"S.S>WE PWA.P.QJ1UQS[P5%*U $X
MRGWK (Z=,'F^N)ZX&W"T:.':6EA=S8[U??O"J3WA85G"J9:-P6L3O7U,PW/S
MF553>_E!$G^D)L6KIC"MX:C@8/0X%K Y^7PUO>:;C+&.;QWGAX[(8WXY<[3V
M0P-W?:&;IS$9;L6TO*G%]>4$SUV!V)(QW_#!4AU]7U+_ "ZP43W]>4$&/S -
MB3ZS\,-2'W/>OHBA[^O*"X_2_P"Q.?[L52_Y+Z(GOZ\H+C^D!L2"/[<-2.>A
M_P#U7Z=?O^S1%$7UY0/QV V)'_?AJ1__ "OHBE-]>4%^P!L3W]WPPU+N'M]Z
M_C]S&B*(OKR@F>NP&Q..G3X8:ETZ=?ZE_ ]/ET185N#B!XU[?WGLW;B5PX;,
M+NZ_J'59]/J;>\TY,!BG4&#5JB]&D(-G+7S.)HTDI7VZ0E3J"4*"<*Z$[%G;
M%7:OKVQ5%$&CZDEP%*G3IQZSU@^UN3]BP,0<SROI/^;-PY:[V2YV]OVEQ)LW
M=M$\3<3J0,SN7IY0%?*4;"['$*0E2@=X9Y"5DD*2/Z%<J 2$D*\>8C QD^B<
MZF6;K6%KHC>+@X<O9W6ZDVG@.*Z\TZA=(J")F"SEE8\A>)ZU%-[^4$&,[!;%
M>CW?FPU(!7?U(%K'&?'X^[7':PM<3O2#-HCJO/F N0"W=(+27:'>@#_=B_>%
M-[^O*"YS\ &Q('J^&&I=>A\?>OTZXUL6*C[^O*"=_P  &Q/AT^&&I=/7U]Z_
MXXT1/?UY0/[ &Q([_P"O#4OD_J7\?X-$0WUY03'38#8G..[X8:EW_P""_AHB
M>_KR@G=\ &Q/=]-\,-2[\=^/>OZ]$4/?SY07&?@!V(!]7PP5+P]OO7/?]SY]
M$0WUY03/38#8G 'V8:EU/J^I?IHBP=OON_QEV5;-,NF_.&39*N4WWU69:\>)
M$WMJ\)SW0O:[J-9]-><=;M1SF9ASZ]&FN,*;4)2&51@MDNAYOI\?L;";1Q-#
M$XBG3>Z@S<;OM>26ESG1+:C!$ND @WO*YF'QC\.Q[&EXWS/LEH@@ 3[3'7M!
M/#*#=9:IUX<?K<6((_#]L;';+/)R-;QSE1@RV5&.EI'O2"V5)0K#O:./]HH9
M26\8/<4*6%P]/<90<V"+,J!K8 C(TWFW-Q6#\13J ;U)SC+C)J7O )/L#@(Y
MW7TS>WE!\ )V%V,&#WG>&H$D>T^]8#'3NP#]W.FM3?4(]75-( @P6A\C43[.
M?&%H);-FP.!)/R53W]>4$Z?F [$]W4_##4NA]?U+]?DUN6*"^?*"XZ[ [$9_
MNP5+P\,^]?Q]>.F?F(AOKR@OAP_[$CK]F*H]1ZOJ7T11%]>4$R<[ ;$XST/P
MPU+N^+WK^'=HB"^?*"9Z[ [$X'0?FP5+UY_6OTQW8^71$%]>4$)Z[ ;$C'A\
M,-2.?_)?IC1% WUY03KC8#8GV'X8:EZ^[!M?1%8VY>XG'13+&NBOW)PY;'5*
MAVQ0:O<U4@L;S59B1)AT"GR*L\RQ(:MCG9<=3#Y.U"7 A*B5-K *3Q,7@L-C
M6,9B:3*K:;Q4:'AQW7 $2-US3D2#<@C1<G#8DX9SW@/.\PL(8X--R+F65 0,
MX@&0#-H/P=G=VN-V\]N+0O&R^&S9&B4*YX2JO#I\O>>J/N1X[KKC?9K6JU$.
M//9:4KMRM*2% !H<IS*. PF' %*BQD0;!V?&[G*U\3ZX@D/," 7.!,3,$M8T
M1GD.6665/?QY0;[ 6Q0P>X;PU'NZ>)M<^KH/#VZW.IO,[E3<_P!W> _O#MD]
MRXX+=6DY?RHZ]#FI_?UY04#'P ;$GOPH[PU+)]61[U_BUM:"&@$[Q  )B)(%
MS$F)-XDQQ4,28$";"9@<)M/7">_KR@OV -B3C^W#4NN?_P"%^F/NZJBB;Y\H
M)TQL#L3[?S8:E\WU+^/W-$3W]>4#^P#L2>_^O!4OD'U+_=]FB(;Y\H)U_,!V
M)[C@?#!4N_P.?>O]S1$%\^4$QUV!V)S_ '8*EZAZK7]>=$0WUY03PV V)/L^
M&&I=?_)?IC[N=$5"1>_E!7&'$C8#8H'"5#EWAJ))Y%!9 S:RADA..X]_3KJ%
ME.H"RJS?IG[39B8N+P8@@'+33-;*3VTZC7O:7-;O2UKMTD%I%G0Z(F<CE"PY
MM-O[QM7Z]?T:U>&_9BGJL2^9]IW)YWO+->,^MMT6CUM<A@-V?'[%(CUB(T&5
M]LI79%P. .A":RC@J0BGAWLDS_' QU32-CJ%OQ.*&(@^K<"UK6M!?O0&@"!#
M6S($&8Y1IF<WQY04@D;![%I[\#X8:CUZ#']2V ?Q.I4&\(82SF?:/(Y-\,Y7
M#@C6>7;W]0\5,+X\H*!CX ]B3W]3O!4LCQ_6OU]7RY\-8TVN:V'O]8Z?M;N[
MV0"?>LC$V$<LT-]>4$ZXX?\ 8GV'X8:E][WKZS43W\^4%R =@=B?:?AAJ77Y
M/>OD>K1%'W]>4$&?S =B3ZA\,-2&.O=]2_7_ ">W1% WSY03[ .Q)ST_IP5+
MI[?J7ZX]7CHB&^O*">&P&Q)QCK\,-2Z^O^I?I^.-$43?7E!/#8#8D]/LPU+O
M]7U+_+HBE7?'E!2A0&P.Q!)0H ?#!4ADD=,GWKG&>[.#C.<>&H0' M<):X$$
M<01!':%08()$@$&,I@Y3HM>CNKQ=M[W,[9IX7=BS>C=EQ]QXU9^&ZLKBL)DU
MJJT=2%046NVA2T/4IYTR.U )<".R!0IQ76'8NS14%1F#I,((>''?<=Z0<]\9
MQPR7-?CB]I;^E :-R/6,C=W8B?53:<OQG--<N;R@U9HU0I0V'V*91484B"^Z
MWN_4G%L!]LMEYM!M@=HIL*YDME2>8X'.,YUVK!3I- IL<TM^S#A [-S+M[5P
M*A#P8D:$22>K30Y9<+K8?A;VZN+:;8C;3;F[%TURX[.M"@6_5G*2I9A.RJ53
MF(;DAE+CCJVTON-+6EI3CA;&$\Z\9UIITWL-0O?O[[B1[,0.&9DW'#(<5A38
M& B9,R3$6O''+*RV"UM6Q-$31$T1-$31$T1-$31%26"3G!(  24?3@DGF/7
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M"5+1E0;6<Y0.H0D=!@*P2>XG/*.IQCIHK!UCY?/E81Q.LZ H#TN_V**Q\A4
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M(FB)HB:(FB)HB^9*#HD!32VV<,E2POE0'^52 '5.(^BXBI*T\CJDLJ[?)"B
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M;#-DD*)'0K41[4YZ'14*IHB:(FB)HB:(FB)HB:(FB)HB=^B*EV*<D@J /+D
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MS$JSRCD6G/+C.2I(">_O40#UQG!T21$S;SQR[5,7,%/HJP2 LC&$922">OI
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MDF7*8@\3S[N,GE9<YJUY1[BJW#C;E[S;?;R\/&VM@;:UJI0(&QUVUVQ:??\
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M\SRY1*Q'4.'WRE5^;-0>!VYK6L2F;8TYU-(5O6VN:ZY,LU#BV6Z>:.IY$<3
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M&+LO#X4MIX5M5N@5#;"/>L^\W[UK]=B5:&[)>=DTV@-Q8(54F?-F_,9*DAL
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M  ,)^E'3P'AHD#AR[."!M *2$)!2I2DX Z*7GG4/45<QR>\Y.>\Z*0.Z_O\
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..(FB)HB:(FB)HB:(O_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g236540g63p02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g236540g63p02.jpg
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M(G9EWJVK[K<JUCJ-77UE23G/\?422#&>X!L#P&!QBE;.U16U=03EIJF>7/\
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M*K/$I7$D-N>,AQVI)!J9!%*D>5CC61A*C]=S6]13+%2Q/3R2+B>0L"5&/:6
MC?VCD:V"N!LH#'4)3<(\BO[J/<4BJJK]0^)!55?555,?OEY\_=?X^_[U]^UD
MY)&/0ES"/]%\W?&DJOW\%[4P;ERH/=V-?_J2<,7<O2>9C6_OW76N_P 0<O\
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M22@  BAQ':FOFJ.;%LSQTAME3%34M32FBI6[<2VF(M/),\35#50<AXJCM1)
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MCUP,QPH[&!?K/O4^>[81)3W6-?99135.!T=<F&1O[2EHR>@T1CJ>*8]-9_\
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M"F.+9DI3M))W@S=\:_U-I#T;1C?H;!!"JP@ZVM#%KZZO%'!  !'B$"""$B9
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E2TRB0#';R$RS'8@X=\Z,@X*QA%/>O$I^UHX*\+LN%PNRX7'_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
